Vol 13 No. 2 Summer 2016
Summer 2016
Pharmacy Journal of New England
Influenza Immunization Update 2016-2017 Certificates of Insurance Rx and the Law Will You Avoid these Estate Planning Mistakes? Financial Forum
Get ready for the
New England Pharmacists Convention back at Foxwoods Resort - registration inside!
Endorsed* by:
Should something happen to you...
is your family covered? Life insurance isn’t for you, it’s for them. Do you have life insurance? We can help.
“Pharmacists Mutual Companies is a company built on integrity, professionalism, moral ethics, and above all a gentle and caring touch that ensures your final wishes will truly come to fruition. Pharmacists Mutual is a cut above the rest and has successfully restored my faith in the value of insurance. I would gladly recommend Pharmacists Mutual to anyone without reservation and am forever thankful for their steadfast diligence and desire to make sure my loved one’s final wishes were carried out.”
Protect your family’s financial future with life insurance.
Call us today and experience the Pharmacists Mutual difference.
800.247.5930
Dr. Elizabeth Odumakinde, MD
Tom White
800.247.5930 ext. 7094 508.942.2211 Products underwritten through The Pharmacists Life Insurance Company, a subsidiary of Pharmacists Mutual. * Compensated endorsement. Not licensed to sell all products in all states.
phmic.com
Pharmacy Journal
Vol 13 No. 2 Pharmacy Journal of New England • Summer 2016
of New England
Support those who Support Provider Status Dear Readers, This summer weather and overall climate has been hot – from the political conventions to the Olympic concerns in Rio and the contrast of Black Live Matter protests and support for law enforcement, it is indeed a tempest as people come down on their side of the issues. As all this swirls around us, please know that your State Pharmacy Associations have but one side – YOURS. The associations have been advocating for pharmacists and the advancement of pharmacy for many decades, especially as major shifts in the health care system has occurred. We will continue to do so and ask that you continue to stand with us and encourage your younger colleagues to do so as well. Provider status for pharmacists is within our grasp and when you read through articles and positions of candidates, especially those seeking to represent you in Congress, please make sure they are aware of this critical issue. Many voices standing together will result in forward movement for all of us. Sincerely,
Editors
David Johnson Margherita R. Giuliano, R.Ph., CAE
Managing Editor Ellen Zoppo CPA
Design & Production Kathy Harvey-Ellis
The Pharmacy Journal of New England is owned and published by the Massachusetts Pharmacists Association and the Connecticut Pharmacists Association. Opinions expressed by those of the editorial staff and/or contributors do not necessarily reflect the views or policies of the publisher. Readers are invited to submit their comments and opinions for publication. Letters should be addressed to the Editor and must be signed with a return address. For rates and deadlines, contact the Journal at (860) 563-4619. Pharmacy Journal of New England 35 Cold Spring Road, Suite 121 Rocky Hill, CT 06067-3167 members@ctpharmacists.org
Submitting Articles to the Pharmacy Journal of New England™
Margherita R. Giuliano, RPh Executive Vice President Connecticut Pharmacists Association
David Johnson Executive Vice President Massachusetts Pharmacists Association
The Pharmacy Journal of New England™ is the product of a partnership between the Connecticut Pharmacists Association and the Massachusetts Pharmacists Association. The Journal is a quarterly publication. All submitted articles are subject to peer review. In order to maintain confidentiality, authors’ names are removed during the review process. Article requirements must conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (Ann Intern Med 1982;96 (1part1):766-71). We strongly encourage electronic submissions. PJNE does not assume any responsibility for statements made by authors.
Please submit manuscripts to: PJNE 35 Cold Spring Rd., Suite 121 Rocky Hill, CT 06067 or email to: ezoppo@ctpharmacists.org
Contents 02
04 15 24 27 29
US News New England States Registration Brochure: New England Pharmacists Convention Feature: Important Updates for Influenza Vaccinations, 2016-17 Pharmacy Marketing Group: Rx and the Law, Financial Forum From the Colleges
1
U.S. News The Rise and Fall of Theranos Theranos, a blood-testing startup based in Palo-Alto, California once valued at $9 billion in 2014, went down to a mere $800 million in 2016. This is nothing compared to the CEO and founder Elizabeth Holmes’ drop in net worth. In 2015 32-year-old Holmes topped the Forbes list of America’s Richest Self-Made Women with a net worth of $4.5 billion. As of July 2016 her net worth is $0, reports Forbes. Holmes founded Theranos in 2003 after dropping out of Stanford University at the age of 19. In 2003 Holmes raised money to help fund Theranos, a company she claimed would be able to “quickly process the full range of laboratory tests from a few drops of blood.” Theranos was supposed to revolutionize blood testing by using finger sticks versus the standard venipuncture for a wide array of tests. In 2013 Walgreens bought into the Silicon Valley hype and partnered with Theranos hoping to have their “Edison” blood testing machines in every Walgreens. However, in October 2015 these claims were starting to prove untrue. Theranos’ downfall started on October 15, 2015 when the WSJ published an expose that stated Theranos wasn’t using any of their own technology to run the blood tests. Other publications question consistency and accuracy of Theranos testing. The FDA also conducted two lab inspections in October. Their finding concluded that Theranos was using uncleared medical devices, the “nanotainers” (Holmes mini test tube invention to collect the drops of blood for testing), and poor record keeping. At the end of 2015 Walgreens decided to suspend any further expansion with Theranos testing systems and in June 2016 officially cut all ties with the controversial company. The Centers for Medicare and Medicaid Services (CMS) in 2016 announced that Theranos’ Edison device produces results outside the acceptable range. In addition to inaccurate test results CMS found that Theranos was not keeping their blood samples in correct temperatures and were not notifying patients in a timely manner of their inaccurate results their technology produced. On July 7, 2016 CMS shut down Theranos’ lab and barred Elizabeth Holmes and other owners and operators from owning or operating a lab for a period of two years. Theranos is suspended from Medicare and Medicaid payments 2
approval, and they have been fined. In addition to CMS shutting down Theranos the company is also under investigation by U.S. attorney’s office about whether or not they misled investors about their technology. Less than a year ago Elizabeth Holmes had a net worth of more than $4 billion and led what some use to believe one of the greatest opportunities of healthcare technology advancement. Now, she is now worth nothing and is banned from owning a lab for a least 2 years. Everything Holmes worked on for the last 13 years since she was a 19-year-old college dropout means nothing now that CMS suspended her lab privileges and revoked her company’s licence. Elizabeth Holmes is Silicon Valley’s own cautionary tale. http://www.wsj.com/articles/under-fire-theranos-ceo-stifledbad-news-1468195377 http://money.cnn.com/2016/06/01/technology/elizabethholmes-theranos-forbes/ http://fortune.com/2015/10/31/theranos-timeline/
Medicare Saved $165 Million in 2013 All Thanks to Medical Marijuana Health Affairs published a study that collected and examined data from Medicare Part D from 2010 to 2013. It was the first study ever conducted to see how medical marijuana could possibly change healthcare costs and if it could alter doctor’s clinical practices. States that have legalized medical marijuana have already seen a drop in medicare prescriptions for disease states such as chronic pain, depression, and anxiety to name a few. Medicare Part D also noticed a decline in their spending, money that would usually go to cover prescriptions costs for those disease states. The study believes that the legalization of medical marijuana and a drop in certain Medicare Part D prescriptions are correlated given the fact that medications such as blood thinners, a disease state medical marijuana does not treat, saw no decline in prescription numbers or coverage needs. As of July 2016, 25 states including Washington D.C. have all legalized medical marijuana. More states such as Florida and Missouri are going to hold votes later in this coming year to whether or not legalize medical marijuana. Marijuana is currently classified as a schedule 1 drug, however, “A federal agency is considering reclassifying medical marijuana under national drug policy to make it more readily available.”
Pharmacy Journal of New England • Summer 2016
reports NPR. The study concluded that medical marijuana saved Medicare about $165 million in 2013. Researchers believe that if medical marijuana was available nationwide, Medicare Part D in the same year would save about $470 million in costs. This is about 50% of what the program spends in total. Some economists and doctors alike have their own reservations about legalizing marijuana and the true overall cost it would save not only federal programs but people outof-pocket costs as well. To read more about this study visit www.npr.org.
Dermatology [AAD] criteria, sun protection factor [SPF], or vehicle) could be used to predict price per ounce.” There was a total number of 6,500 sunscreen products listed on Amazon.com. Of that total number, only 65 products met criteria of the top 1% and were evaluated. Of the 65 sunscreen products 40% did not meet the American Academy of Dermatology (AAD) guidelines. To learn more about the most popular brands of sunscreen on the Amazon.com market and if they meet AAD criteria or not please read the study here.
http://www.npr.org/sections/healthshots/2016/07/06/484977159/after-medical-marijuanalegalized-medicare-prescriptions-drop-for-many-drugs?utm_ source=facebook.com&utm_medium=social&utm_ campaign=npr&utm_term=nprnews&utm_content=20160706
http://archderm.jamanetwork.com/article.aspx?articleid=2532615
The Most Popular Sunscreens May Not Be the Best Sunscreens
The opioid crisis seems to be growing by the day. The U.S. Health and Human Services (HHS) announced early this summer several new actions the department is going to try and implement to help slow down and hopefully stop this growing opioid epidemic. HHS wants congress to approve the President’s $1.1 billion budget to help execute these new actions.
In July 2016 JAMA Dermatology published a study evaluating the most popular brands of sunscreens being sold on Amazon.com this summer. The objective of this study was “to determine the characteristics and the most commonly cited positive and negative features of highly rated sunscreens described by consumers” on Amazon.com. The study focused on the top 1 percentile of sunscreens as of December 2015. The criteria used to determine which sunscreens made it to the top 1% was a combination of number of reviews a product received crossed with the average consumer review of >4 stars. The study also used the top 5 “most helpful” reviews whether they be positive or negative in 6 categories, “affordability, cosmetic elegance, separate ratings, product ingredients, product performance, and skin compatibility.” The study ran a Kruskal-Wallis test, which is a test that lets researchers see if there are any statistical significant differences between two or more independent samples of equal or different sample sizes. The test does not assume normal distribution allowing researchers to make less stringent assumptions regarding the different samples being compared. The study used this test to see if “whether characteristics of each product (eg, American Academy of
U.S. Health and Human Services Announces New Actions to Combat America’s Opioid Crisis
The new actions would include expanding the access to a medication to help treat opioid addiction known as buprenorphine as well as ceasing any future monetary incentives for practitioners to prescribe opioids. HHS would also like it to be a requirement for all Indian Health Service prescribers and pharmacists to check their respective state Prescription Drug Monitoring Program (PDMP) databases before prescribing or dispensing any opioids. The HHS department would also like to launch more than a dozen scientific studies centered around opioid misuse and pain treatment to help improve and expand prescriber education and create new training programs to help the cause. U.S. Health and Human Services Department created the new actions to help build upon the HHS Opioid Initiative which was put in motion March 2015. The HHS Opioid Initiative has three main focuses, improving opioid prescribing practices, making medication-assisted treatment (MAT) for opioid use disorder more accessible, and increasing the use of naloxone, an opioid reversal agent. 3
New England Connecticut
term care pharmacies and more well-known retail pharmacies — particularly the additional requirements already imposed on LTC pharmacies under Medicare and Medicaid Requirements of Participation and Medicare Part D rules,” Rosenbloom said.
As a pharmacist on the front line, I have been working with the CPA Board and my pharmacist colleagues to raise awareness concerning the current opioid crisis.
Long-term care pharmacies’ tracking, auditing, packaging and dispensing of drugs helps them meet the “extraordinarily high” safety standards for Medicare Part D, Rosenbloom said. He also stressed the fact that pharmacists and licensed facility staff are the ones handling the prescription orders, not the beneficiaries themselves.
President’s Message
Deaths from opioids like painkillers and heroin have reached epidemic proportions in recent years, killing 47,000 people in 2014 and surpassing car accidents as the No. 1 cause of injury death. In Congress, both parties Jacqui Murphy CPA President, 2015-16 have agreed the issue needs to be addressed, but funding has been an ongoing area of discussion. Recently the CPA became aware of a bill that would exempt long-term care pharmacies from a controversial “lock-in” provision . This received final passage from the Senate in midJuly and now heads to the President’s desk. With so much information out there every day, in the newspapers, on TV, and on social media, it is interesting that some people missed this, which is why I think it’s important to cover it here. The Comprehensive Addiction and Recovery Act includes language that would require Medicare Part D beneficiaries to use one pharmacy for all prescriptions, in an effort to lessen opioid abuse. Long-term care pharmacy advocates condemned the “lock-in” clause, arguing that legislation already existed that protected beneficiaries in long-term care settings from drug abuse. Alan Rosenbloom, president of the Senior Care Pharmacy Coalition, praised the passage of the bill with the LTC exemption intact. “The exemption is a vital provision that specifically recognizes the unique characteristics of the long-term care patient population and the distinctions between specialized long4
“CARA strikes the right balance between protecting our citizens and communities on the one hand, and protecting the ability of LTC pharmacies to meet and manage the medication needs of LTC residents on the other,” Rosenbloom said. Obama is expected to sign the bill. CARA is estimated to receive $581 million in funding, which is set to be authorized by Senate Republicans in September after Congress’ summer recess. And, as a reminder, please note that there are new CT Laws regarding Controlled Substances that went into effect on July 1, 2016. An Act Increasing Access to Overdose Reversal Drugs goes into effect today! What this means for you: 1. Requiring municipalities to update their existing emergency medical services plans to ensure that the emergency responder likely to the first person on the scene of an emergency call is equipped with and prepared to administer the overdose reversal drug naloxone and has been appropriately trained to do so 2. Closing a gap in current liability language related to a licensed health care professional who administers an opioid antagonist 3. Prohibiting commercial health carriers from requiring prior authorization for coverage of naloxone 4. Each pharmacy must report all controlled substance prescriptions dispensed immediately into the PMP but in no
Pharmacy Journal of New England • Summer 2016
event later than the next business day. 5. Limiting the prescribing of opioid drugs : An initial prescription for adult patients is limited to no more than a seven day supply. For minor patients, any prescriptions for opioid drugs are limited to a seven day supply and the prescriber is required to discuss the risks associated with the drug with the patient/guardian or caregiver 6. Allows for both adult and minor patients, a prescriber to give more than a seven-day supply of opioid drugs if, in the prescriber’s professional medical judgment, the acute or chronic pain condition requires it and requires the prescriber to note such condition in the medical record
Click here to read the bill. The relevant section noted below begins on Page 9. Please stay tuned to the weekly Fast Five newsletter to stay attuned to the pharmacist’s role in fighting the opioid epidemic. We also ask that you do your part as the most accessible health care provider to counsel your patients on the risks associated with the use of opioid drugs. Encourage them to dispose of the drugs properly if they don’t finish the prescription. Jacqui Murphy President
7. Makes several changes to the state’s electronic prescription monitoring program to help facilitate prescriber and pharmacist compliance
A Word from Pharmacists Mutual It is vitally important for everyone to protect their greatest asset – their ability to earn an income. Disability income coverage is available through PMC Advantage Insurance Services, Inc., a subsidiary of Pharmacists Mutual. Life can happen in an instant, so protect your financial future with disability insurance. Call 800.247.5930 ext, 4090 to speak with a Coverage Advisor or visit www.phmic.com for more information.
5
New England States
continued
Massachusetts President’s Message Dear Colleagues, Have you ever felt unsafe at work? More often than not, I do feel safe at work. However, I felt vulnerable in 2012 when I was robbed at gunpoint. The masked man entered through the front door, brandished his revolver, demanded specific narcotics, and threatened to kill us if we did not comply. The frightening ordeal lasted only Karen Horbowicz 80 seconds. Although no one was MPhA President, 2015-16 physically harmed, the incident haunted me for months. Like many of you, I spend a significant amount of time at work, making it my second home. I took it personally, felt violated, and became angry. This was one of the three driving forces behind Operation Prevention. I desperately wanted to share my experience so others could learn from it. Additionally, we are planning to perform a needs assessment to determine how prepared pharmacy personnel are to handle robberies and aggressive patient behavior. We have identified an instructor to provide safety training to those who need it. We will be sending out a survey shortly. Please complete the survey or contact MPhA if you are interested. The second and third driving forces behind Operation Prevention are my children. As a parent, I am saddened by the personal stories of addiction and am concerned about the future for my children. One of my former students graduated from high school eight years ago. In that time, ten of her friends have died from an overdose while several others continue to struggle with addiction. Pharmacists have the power to do something about this now. MPhA will continue to work with the MOON study (Maximizing Opioid Safety with Naloxone) investigators and community pharmacists to provide strategies for increasing naloxone distribution. With the assistance of Vivian Tahmasbi, a sixth-year pharmacy 6
student, we have partnered with a number of Massachusetts Opioid Abuse Prevention Collaborative Coalitions to engage pharmacists in the prevention efforts and further the coalitions’ reach within the communities they serve. We have developed a tool kit for pharmacists to use when dispensing controlled substances. With the assistance of Amit Hirani, another sixth-year student, we have redesigned our Operation Prevention website to better highlight the available resources. Operation Prevention can be found under the resources tab on our website, http://www.masspharmacists.org/. We continue to work closely with the Department of Public Health to roll out the new MassPat Prescription Monitoring Tool, which will go live on August 22, 2016. If you have not already done so, you may sign up for your new account at https://massachusetts. pmpaware.net/login. I strongly encourage you to visit our website frequently as we continue to add new resources as they become available. Additionally, we are actively recruiting new members to join our vital Operation Prevention efforts. If you are interested please contact the Association, djohnson@masspharmacists.org.
Events In conjunction with the New England Pharmacists Convention, MPhA will hold its 133rd Annual Installation and Awards Banquet on Thursday evening, September 22nd at Fox Tower in Foxwoods Resort & Casino. Please join us for this opportunity to celebrate the accomplishments of pharmacists who have earned recognition through their contributions to the profession and our communities. The festivities will begin with a cocktail reception at 6:00 pm. Tickets can be purchased at www.masspharmacists.org. MPhA will offer 7 hours of live CE at the first annual MPhA Western Massachusetts Fall Conference, which will be held in River’s Auditorium on the Western New England University campus in Springfield, MA. Registration will open shortly.
Legislative Update We are pleased to announce a new law we have been working on for the past two years! Section 63 of the state budget authorizes pharmacists to administer mental health and substance abuse medications via injection on the order of a prescriber. The Governor sent this section back to the
Pharmacy Journal of New England • Summer 2016
legislature with an amendment that called for regulations from DPH in consultation with the Board of Pharmacy and the Dept. of Mental Health, which could have delayed the implementation of this policy for years. However, the legislature rejected the amendment and attached an emergency preamble to make the law effective immediately! This will be an important tool to help patients with diseases such as schizophrenia to receive their monthly injection at a conveniently located pharmacy and boost adherence rates for this population. We will continue to provide members with updates. H.2041, An Act Recognizing Pharmacists as Healthcare Providers was reported out of the Joint Committee on Public Health unchanged, with a recommendation that it ought to pass. The bill was referred to the Joint Committee on Health Care Financing. MPhA staff and volunteers have begun
meeting with the Committee members to continue to push this bill forward. In addition, the Board of Pharmacy has undertaken an ambitious rewrite of existing pharmacy regulations and added proposed sections necessitated by the new license categories for sterile and complex non-sterile pharmacies. The proposed new and redrafted regulations are beginning to appear for public comment. Please visit our website, www.masspharmacists.org under the State Advocacy tab to view the proposed regulations. You can help MPhA draft our comments and suggested amendments by sending your ideas and insights to David Johnson at djohnson@masspharmacists.org For the honor and opportunity to serve the Association as President, and for the all the help and support I have received from members, fellow board members, and staff, I thank you.
MPhA Western Massachusetts Fall Conference November 2, 2016, 8:00 a.m. to 4:30 p.m. Western New England University, Rivers Auditorium in collaboration with WNEU’s College of Pharmacy 7 hours of ACPE accredited Continuing Education Pipeline Preview 2016 (0.1 CEUs), by Maria Lowe, PharmD, Clinical Pharmacist, PatientsLikeMe Eye Care 101 for the Pharmacist, by Andrew McLeod, OD, MSc, FAAO, FBCLA, Associate Professor, New England College of Optometry, Boston, MA Update from the Board of Pharmacy (0.1 CEUs - Law), by David Sencabaugh, RPh, Executive Director, Massachusetts Board of Registration in Pharmacy The Current and Future Roles of the Pharmacist to Maximize Safe Opioid Use: Focus on Naloxone (0.1 CEUs - Law), by Jeffrey Bratberg, PharmD, University of Rhode Island, and Traci C. Green, PhD, MSc,Deputy Director, Boston Medical Center Injury Prevention Center & Boston University School of Medicine, Department of Emergency Medicine Herbal Supplements: all natural or profit factories (0.1 CEUs), by Nancy Balch, PharmD, Senior Attending Pharmacist, Emergency Department, Massachusetts General Hospital Operation Prevention: Pharmacy Safety and Substance Abuse Prevention, by Karen Hobrowicz, Pharm.D. , Inman’s Pharmacy, Cambridge, MA Hypertension Update: How to give Meaning to your Screening (clinically meaningful interventions for the community pharmacist), by Courtney Doyle-Campbell, Pharm.D., Clinical Assistant Professor of Ambulatory Care,Department of Pharmacy Practice, Western New England University College of Pharmacy Continental Breakfast, Lunch, and refreshments are included. Registration will open soon at www.masspharmacists.org 7
New England States
continued
New Hampshire Legislative Day Health Fair On Wednesday, May 18, the NH pharmacy associations, including the NH Pharmacists Association (NHPA), NH Society of Health-System Pharmacists (NHSHP) and the NH Independent Pharmacy Association (NHiPA) were represented as part of the Intra-Organizational Counsel (IOC), sponsored a booth at the Legislative Day Health Fair at the Legislative Office Building in Concord, NH. Legislators were on hand to visit the various booths manned by healthcare providers. Educational materials presented by pharmacists and pharmacy students included naloxone and proper medication disposal. This unique opportunity for dialogue between legislators and pharmacists was well received. Pharmacists educated our legislators regarding the various services we provide to the community, and the need for expanding the scope of pharmacy practice such as collaborative practices, provider status, immunizations, etc. This unique opportunity for dialogue between legislators and pharmacists was well received. Similar events are being planned for our upcoming legislative session this fall.
Legislative Update Adopted Rule for Med 502 Opioid Prescribing This rule shall apply to the prescribing of opioids for the treatment of non-cancer and non-terminal conditions. Under this rule, prescribers are required to register (or delegate) with the NH Prescription Drug Monitoring Program. They shall query the prescription drug monitoring program to obtain a history of schedule II-IV controlled substances dispensed to a patient, prior to prescribing an initial schedule II, III, and IV opioids for the management or treatment of the patient’s pain and then periodically and at least twice per year, except when administration in a health care setting and/ or in treating acute pain for no more than 30 days.
8
Jessica Marx performing blood glucose counseling (above)
Above, left to right: Lorraine Radick, Jay Calabro and Harriet Petrulio.
New Hampshire H.B. 1664 signed by the Governor on 6/3/2016. Chapter Law: Chapter 177. Summary of Final Bill: This bill does the following: • Establishes procedures for contracts between pharmacy benefit managers and contracted pharmacies. • Provides that all contracts between a pharmacy benefit manager and a contracted pharmacy must include: o The sources used by the pharmacy benefit manager to calculate the cost of a drug dispensed to a patient and does not contain a dispensing or professional fee, o A process to appeal, investigate or resolve disputes
Pharmacy Journal of New England • Summer 2016
regarding maximum allowable cost pricing, o A 30-day time limit to appeal after the initial claim, o Resolution of appeals in 10 days, and o If the appeal is denied, the reason for the denial and the pharmacy benefit manager must identify the national code of a drug of a drug product that may be purchased by contracted pharmacies at price or at below maximum allowable cost. o Requires a process to provide for retroactive reimbursements. When the pharmacy benefit manager establishes a maximum allowable cost to determine the drug product reimbursement, the PBM is required to: • Include in the contract the identifying national drug pricing compendia or sources used to obtain drug price data. • Make available to the contracted pharmacy the drugs subject to maximum allowable cost and the actual maximum cost for each drug. • Review and adjust the maximum allowable cost for every drug at least every 14 days. • Make available to the contracted pharmacy weekly updates to the list of drugs subject to maximum allowable cost for each drug.
Telemedicine. • Authorizing the BOP to create rules on the price of filling prescriptions paid by PBMs and insurance. When: This law has multiple effective dates on 6/9/2016 and 8/8/2016.
New Hampshire H.B. 1681 signed by the Governor on June 6, 2016. Summary of Final Bill: This bill establishes a commission on hypodermic syringes and needles. The commission’s study shall include, but not be limited to: • Studying the national standards for best practices for syringe services programs. • Discussing the feasibility of implementing syringe services programs in New Hampshire. • Identifying recommended solutions, both legislative and non-legislative. • Reviewing any other matter the commission deems relevant to its objective. When: This law is effective from 6/6/2016 until 11/01/2016. Report due November 1, 2016.
When: This law is effective on 1/1/2017.
New Hampshire H.B. 1490 Amended Effective August 6, 2016.
The NHPA board of directors wish to take this opportunity to thank Richard Cohen for his diligence and hard work on this bill.
NH Rev. Stat. 318:16-a: Standards for Collaborative Pharmacy Practice
New Hampshire H.B. 1210 signed by the Governor on 6/9/2016. Summary of Final Bill: This bill does the following: • Clarifies when it is appropriate for practitioners to adjust or prescribe controlled drugs to patients by telemedicine. • Adds rulemaking authority for the pharmacy board concerning the price of filling prescriptions paid by a pharmacy benefits manager or insurer. The bill also adds authority for the insurance department to adopt rules for enforcement of requirements for the price of filling prescriptions. Impact: The Bill would impact pharmacy by: • Clarifying when controlled drugs may be prescribed by
Summary of Final Bill: This bill does the following: • Clarifies requirements for pharmacist participation in collaborative practice agreement. • Practice agreements may be between single or multiple pharmacists and a single or multiple practitioners. • A service authorized by a practitioner to be performed by a pharmacist under a collaborative pharmacy practice agreement must be within the practitioner’s current scope of practice. • Collaborative pharmacy practice agreements shall meet the following general requirements including drugs used, therapy implementation, protocols and defined supervision. The bill was signed by the Governor on June 7, 2016. It is Chapter Law 214, and the effective date is August 6, 2016. 9
New England States
continued
The NH Board of Pharmacy must rewrite the current rules on Collaborative Practice this fall, so pharmacists may practice per the extent of the new law. Until the current rules are rewritten, Collaborative Practice Agreements are required to follow existing rules. The rules will require input from various stakeholders to ensure rules incorporate the necessary components to safely practice “Collaborative Practice” in the State of NH. The initial meeting is scheduled for Thursday, September 1st.
SB 576 –Relative to the controlled drug prescription health and safety program This bill does the following: • Adds possession and use of fentanyl-class drugs for the purposes of the penalty under the controlled drug act. • Clarifies the funding of the controlled drug prescription and safety program. • Clarifies access to the information of the controlled drug prescription health and safety program. • Requires prescribers of controlled drugs to query the controlled drug prescription health and safety program prior to prescribing controlled substance. • Must take 3 hours of continuing education or an online examination. • Adds 2 physician members to the medical review subcommittee. • Clarifies substance use disorder services for treatment for an addictive substance related condition under the Medicaid managed care program. • Requires the commissioner of the department of health and human services to consult with the commissioner of the department of safety regarding a 24-hour drug crisis hotline. This bill is a result of the Joint Task Force on Heroin and Opioid Epidemic’s work in December 2015. Signed by the Governor on January 21, 2016.
A New Grad’s Perspective -- APhA Institute on Alcoholism and Drug Dependencies by Jessica Marx, PharmD In our world today, it seems as though not a day goes by where you don’t hear someone talk about the opioid epidemic. It’s a problem which faces us as a nation, but especially as pharmacists, on a daily basis. Unfortunately, our 10
patience and understanding is tried on a daily basis when we are asked to fill controlled substances early, when we’re selling ten pack after ten pack of hypodermic needles and while we’re constantly treating patients in our ICUs for overdoses. These common occurrences make it so very easy for us to pass judgment, forgetting about the people behind the disease. This past June, I was fortunate enough to attend the APhA Institute on Alcoholism and Drug Dependencies in Salt Lake City, UT for the second year in a row. After my eye-opening experience last summer, I wanted to not only attend again, but give back to the program. I was selected as an ambassador, and am grateful to have contributed to such an impactful four days. The APhA Institute educates many pharmacists, student pharmacists and others every year about many different facets of addiction. And not only that, the APhA Institute puts a face to addiction allowing us to take a step back to be reminded of exactly who these addicts are: people just like us. Some of the kindest, most caring and thoughtful people I’ve met are surprisingly enough, recovering addicts. The APhA Institute has certainly helped to further my education on many topics regarding addiction, especially considering how little exposure we receive in formal education. More importantly, the APhA Institute reminds me that these patients are struggling, just like any other, and need my understanding and compassion now more than ever. They don’t deserve the stigma attached to their addiction, and we as pharmacists should recognize that better than anyone. Whether an underlying mental illness, a serious injury or a difficult time which led them on this destructive path, each of these people has a story to tell, but often, you’ll never hear that story. Addicts live behind a veil of shame. They will tell you time and time again that they don’t want or need help and their shame is the reason. But perhaps the next time you fill a prescription for Suboxone, introduce yourself. Ask that patient if they have any questions about their medication and counsel them appropriately. Let them know that you’re there for them as they begin their road to recovery. For a patient with a newly prescribed opioid for their acute pain, by counseling this patient to only take this medication as needed due to risk of dependence and then discarding the remainder
Pharmacy Journal of New England • Summer 2016
could greatly make an impact on that patient or even their family member. You never know the difference that the five minutes you take out of your day can truly make. As a new practitioner, I must say that I wish our profession was better educated about this disease. We, after all, are the most accessible healthcare professionals and according to the most recent Gallop poll, the second most trusted professionals in the United States. It is often the drugs we dispense which sparks it all. By recognizing addiction as a disease rather than solely a choice allows us to better care for our patients and helps to combat the stigma associated with addiction. In addition to this, realize what we can do in our roles to help prevent and control this epidemic. Learn more about naloxone and its role in opioid addiction. In fact, get trained on how to administer naloxone. You never know when it might come in handy. Come from a place of support rather than judgment when interacting with these patients or their families. Strongly consider attending the APhA Institute in Salt Lake City next June. I promise, you will not regret it. And most importantly, remember why you went to pharmacy school in
the first place. For most of us, I think it was to help others and better the lives of our patients. And together as pharmacists in our local communities, this is the perfect opportunity to do just that. Perhaps Margaret Mead said it best: “Never believe that a few caring people can’t change the world. For, indeed, that’s all who ever have.”
Upcoming 2016 Continuing Education Conferences Remember, save the dates for upcoming CE programs in 2016 which are as follows: Sunday, September 11, 2016, LaBelle Winery, Amherst, NH Sunday, December 4, 2016, SERESC, Bedford, NH Details and directions can be found on our new website at www.nhpharmacists.net . Also, please join our Facebook page by searching “NHPA”.
(Left to right) Corey Chase and Enoch Amarh from MCPHS-Manchester and Jessica Marx, PharmD at the APhA Institute on Alcohol and Drug Dependencies
11
New England States
continued
Rhode Island New RIPA Officers Elected Congratulations to our newly elected Officers and Council of Administration! The 2016-2017 RIPA Officers and Council, whose term began on July 1st, are looking forward to working hard for you, our valued members, over the next year! Officers President: Sarah Thompson President Elect: Lucrezia Finegan Past President: Lynn Pezzullo Treasurer: John Grossomanides Secretary: Virginia Lemay Council of Administration Christopher Federico Kenny Correia Patrick Kelly Anthony Harrison Madeleine Ng
Christine Eisenhower Daniel Lefkowitz
News In RI Legislative news, a new bill expanding collaborative practice in RI to allow pharmacists to initiate medications was signed into law by Govenor Raimando in June. This bill will allow pharmacists to work more collaboratively with physicians, provide medication therapy management services and close medication gaps in care for patients. The RI General Assembly also passed the first bill in the country mandating Naloxone insurance coverage for “use in persons other than the insured.� This bill removes a barrier for anyone who wants to help defeat the opioid overdose epidemic in Rhode Island. Out 18th Annual RI Pharmacy Foundation Golf Outing at Warwick Country Club in Warwick, RI was a success, drawing golfers from all over the state! We were successful in raising funds for scholarships to support student pharmacists, our future pharmacy leaders. Congratulations to our first place winners of the Golf Outing: Ben Weinstein, Brett Lareau, Zach Conley, and Nicole Russo! We look forward to planning and sharing the details of our 19th Annual Golf Outing in the Spring of 2017. Congratulations to our 2016 RIPA raffle ticket winners! The lucky raffle ticket winders are drawn at the Annual Golf Outing, with no more than 250 tickets available
(Left) The 18th Annual RIPA Foundation Golf Outing
12
Pharmacy Journal of New England • Summer 2016
for sale. If you missed out on buying a winning ticket, be sure to be on the lookout for ticket sales from your RIPA Officers and Council of Administration members in the Spring! This year’s winners are: $5,000 winner: Mike Sherry $1,000 winner: Alexandria Gerlach
and Council of Administration and recognize the achievements of our 2015-2016 RIPA leadership teams. The Awards Ceremony will highlight the outstanding achievements and contributions of many talented and dedicated pharmacists and pharmacy supporters in Rhode Island.
Get Involved with RIPA
$500 winner: Chris and Angela Martin Franklin $250 winner: Christopher Albanese $250 winner: Maggie Charpentier / Michelle Caetano $250 winner: Norman Campbell
We welcome you to attend Council of Administration meetings. This is a great year to get involved in RIPA through active committee participation and event attendance. If you are not yet a member of RIPA please join today! Visit our website to learn more: ripharmacists.org
Be sure to register now for the New England Pharmacists Convention at Foxwoods Resort and Casino in Mashantucket, CT and for our 142nd RIPA Presidents Dinner and Awards Ceremony on Thursday September 22nd 2016. At the RIPA Dinner we will formally install our new Officers
1-(877)-360-0095 www.buy-sellapharmacy.com
Your Local Specialist Jack Collins, R.Ph. jackc@buy-sellapharmacy.com Tel: 1-(203)-395-6243
Completely Confidential!
Don’t Leave Money On The Table
when you transition the ownership of your pharmacy. • If you are talking with a buyer (particularly a chain buyer), have an offer on the table, haven’t signed anything yet, TALK TO US LAST!! •
If you are contemplating a sale but haven’t begun to consider the issues involved, TALK TO US FIRST!!
•
Either way, all conversations are TOTALLY CONFIDENTIAL AND TOTALLY WITHOUT OBLIGATION. THEY COST YOU NOTHING!
Don’t be fooled by web sites or advertisements that purport to tell you EXACTLY HOW MUCH you are leaving on the table. There are no absolutes when selling a business and EVERYTHING is negotiable. Visit our website to view a list of references that you can contact.
A 15-year track record of successfully completing more than 400 independent pharmacy sales.
.
13
New England States
continued
Maine MPA Fall Convention, Trade Show, and Award Banquet The Maine Pharmacy Association Fall Convention and Trade Show has lined up outstanding speakers to educate our pharmacy community on topics relevant to the profession. Also included in the continuing education option is CPR recertification. The convention is scheduled to run from September 9-11, 2016 at the Hollywood Casino, Bangor, Maine with our annual awards ceremony being held on Saturday, September 10, 2016. For more information please visit MPARX.com.
Maine’s Congressional Delegation Supports S314 Senator King has co-sponsored S314, the Pharmacy and Medically Underserved Areas Enhancement Act. This news marks one year since MPA visited each representative advocating for their support. This bill and the House companion bill, HR592, would amend the Social Security Act to recognize pharmacists as healthcare providers and significantly enhance access to cost-effective services. Senator King joins Senator Susan Collins and Representatives Chellie Pingree and Bruce Poliquin on this issue which makes for 100% support from Maine’s congressional delegation. The profession of pharmacy has never been closer to achieving provider status.
Maine’s New Opioid Prescribing and PMP Law Takes Effect The Maine Pharmacy Association (MPA) Legislative Committee through the leadership of Kenneth McCall and Amelia Arnold provided input to protect the interest of pharmacy professionals, patients, and the profession on bills addressing the opioid crisis in Maine, LD1646 and LD1547. The committee successfully advocated for common sense modifications to bills that directly affect pharmacy and protect patients. Amendments to bills include: LD 1646 - An Act to Prevent Opiate Abuse by Strengthening 14
the Controlled Substances Prescription Monitoring Program (PMP): Changes from the original bill now only require a pharmacist to use PMP in limited scenarios instead of every prescription, exempt vulnerable patient populations from prescribing limits, and language for immunity for dispensers. LD 1547 - An Act to Facilitate Access to Naloxone Hydrochloride: The addition of the immunity clause is the single most important amendment. The law now states that “a health care professional or a pharmacist, acting in good faith and with reasonable care, is immune from criminal and civil liability and is not subject to professional disciplinary action for storing, dispensing naloxone hydrochloride in accordance with this section or for any outcome resulting from such actions.” Maine’s new opioid prescribing and PMP law took effect July 29th, though some provisions have other timeframes specified in the law. The impact of this law will significantly affect prescribers, pharmacists and patients. Specifics on the bill can be found on MPARX.com under Legislative Updates.
Celebrating 150 Years The Maine Pharmacy Association, the first professional state pharmacy association in the country, will be celebrating our sesquicentennial in 2017. To mark our 150th year, we will be hosting a showcase event the weekend of October 13-15, 2017 in Portland, Maine. Mark your calendars.
12th Annual New England Pharmacists Convention September 22 and 23, 2016
The Fox Tower, Foxwoods Casino, Mashantucket, CT
Registration Information
Presented By The Connecticut Pharmacists Association, The Massachusetts Pharmacists Association, & The Rhode Island Pharmacists Association www.nepharmacists.org info@masspharmacists.org
New England Pharmacists Convention 500 W. Cummings Park, Suite 3475 Woburn, MA 01801
15
Schedule of Events Thursday, September 22, 2016 7:30 a.m. – 8:00 a.m. Certificate Program Registration & Continental Breakfast 8:00 a.m. – 5:00 p.m. Certficate Training Programs: -Pharmacy-Based Cardiovascular Disease Risk Management -Delivering Medication Therapy Management Services in the Community -The Pharmacist and Patient-Centered Diabetes Care 12:00 p.m. – 1:00 p.m. Convention Check In & Registration Regular Programming Begins at 1:00 p.m. 1:00 p.m. – 2:30 p.m. Thinking Outside the Bench: Alternative Approaches to Pain Management for the Pharmacist to Consider
Hotel Information
ACPE: 0106-9999-16-030-L04-P; 0106-9999-16-030-L04-T; (0.15 CEUs)
A Panel discussion, moderated by Karen Horbowicz, PharmD, Inman’s Pharmacy, Cambridge, MA
The Fox Tower at Foxwoods Resort Casino 39 Norwich Westerly Road Ledyard, CT 06339 Phone: 1.866.646.0050 Website: www.foxwoods.com
Upon completion of this activity, participants should be able to: 1. Identify the principles and benefits of massage therapy that pharmacists should understand for patients suffering from chronic pain. 2. Understand the application of acupuncture as an adjunctive therapy for chronic pain. 3. Evaluate options in extemporaneously compounded medications for the treatment of chronic pain.
The special room rate is $139 plus tax, per night. To make a reservation call 1-800-369-9663 or register at: www.nepharmacists.org Deadline for the special rate is August 31, 2016.
2:35 p.m. - 3:35 p.m. An Inside Look: GI Tract and IBS
ACPE: 0106-9999-16-031-L01-P; 0106-9999-16-031-L01-T; (0.1 CEUs)
Presented by: Nicole Asal, PharmD, University of Rhode Island School of Pharmacy Upon completion of this activity, participants should be able to: 1. Describe the pathophysiology of irritable bowel syndrome (IBS) and how it differs from inflammatory bowel disease (IBD). 2. Summarize goals of therapy for treatment of IBS. 3. Identify pharmacologic and non-pharmacologic treatments for IBS. 4. Name adverse effects & counseling points associated with pharmacologic treatment for IBS. 3:35 p.m. - 3:50 p.m. BREAK 3:50 p.m. - 5:20 p.m. Working in the Pharmacy Grey Zone: Protect Patient Safety, Follow the Law and Remain Ethical--LAW CE
ACPE: 0106-9999-16-032-L03-P; 0106-9999-16-032-L03-T; (0.15 CEUs)
16
The Fox Tower, Foxwoods Resort, September 22 & 23, 2016 Presented by: Dixie Leikach, RPh, MBA; President and Founder of Pharmacy Ethics, Education and Resources (PEER) Upon completion of this activity, participants should be able to: 1. Recall ethical principles identified in the APhA Pharmacist Code of Ethics. 2. Analyze various pharmacy laws that are based on ethical behavior. 3. Distinguish decisions based on ethics versus laws and how to respond accordingly in the best interest of patient safety. 4. Classify the ethical dilemma(s) and appropriate laws within a given scenario. 5:30 p.m. - 5:55 p.m. Association Business Meeting 6:00 p.m. - 9:30 p.m. Cocktail Reception and State Association Banquets
Friday, September 23, 2016 6:00 a.m. – 8:00 a.m. Check In & Registration/Exhibitor Set-Up 6:30 a.m. - 8:00 a.m. Breakfast Symposium One Size Doesn’t Fit All: Applying Pharmacogenomics to Patient Care ACPE: 0106-9999-16-033-L04-P; 0106-9999-16-033-L04-T; (0.15 CEUs)
Presented by: Roseann Gammal, PharmD, BCPS; Pharmacogenomics Clincial Specialist at St. Jude Children’s Research Hospital Upon completion of this activity, participants should be able to: 1. Review genetic terminology relevant to the field of pharmacogenomics. 2. Assess the benefits and barriers associated with applying pharmacogenomics to patient care. 3. Describe the resources available to advance pharmacogenomics into clinical practice.
4. Recommend drug therapy based on pharmacogenetic test results. 5. Define the role of the pharmacist in clinical pharmacogenomics. 7:15 a.m. – 8:15 a.m. Continental Breakfast 8:00 a.m. - 8:15 a.m. Welcome: Alicia Mam daCunha, PharmD, AEC, MPhA President; Bahar Matusick, PharmD, BCPS, CPA President; Sarah Thompson, PharmD, CDOE, RIPA President 8:15 a.m. - 9:15 a.m. Keynote: The Family Perspective on Mental Health and Addiction ACPE: 0106-9999-16-034-L04-P; 0106-9999-16-034-L04-T (0.1 CEUs )
Presented by: Joanne Peterson, Learn to Cope, Founder & Executive Director Upon completion of this activity, participants should be able to: 1. Describe the impact a loved one’s substance use disorder has on the entire family system. 2. Recognize the signs, symptoms and paraphernalia associated with opioid use. 3. Explain the role families have as first responders to opioid overdose and access to nasal Narcan. 4. Describe the unique peer support offered by Learn to Cope meetings and the family discussion board. 9:25 a.m. - 10:25 a.m. Policy Changes to Affect Opioid Safety: A New England Law Update - LAW CE ACPE: 0106-9999-16-035-L03-P; 0106-9999-16-035-L03-T; (0.1 CEUs)
Facilitated by: Jef Bratberg, PharmD, BCPS; Clinical Professor, University of Rhode Island School of Pharmacy Upon completion of this activity, participants should be able to: 1. Compare and contrast statutory and regulatory changes related to opioid prescribing, prescription drug monitoring programs, and naloxone
17
prescribing and dispensing. 2. Describe changes occurring nationally, focusing on the Comprehensive Addiction and Recovery Act. 3. Discuss the benefits and limitations of these changes on your patients and community. 4. Develop strategies to implement and integrate these policy changes into your practice. 10:25 a.m. - 11:00 a.m. BREAK
Student Programming 10:00 a.m. – 11:00 a.m. Interviewing Techniques, Paul LaRochelle Jr., PharmD 11:00 a.m. - 12:15 p.m. Career Path: Roundtable discussion, Small group discussions with pharmacists from a wide variety of practice settings. 11:00 a.m. - 12:00 p.m. Improving Patient Care with Telepharmacy
ACPE: 0106-9999-16-036-L04-P; 0106-9999-16-036-L04-T; (0.1 CEUs)
Presented by: Adam Chesler, Vice President Pharmacy Operations, TelePharm Upon completion of this activity, participants should be able to: 1. Explain why telepharmacy started and how it has evolved with technology. 2. List the different types of telepharmacy and how it is improving patient care. 3. Describe the regulatory environment around the US and what states are doing with rules. 12:00 p.m. - 2:00 p.m. Lunch, Exhibit Hall, Product Theaters
Schedule of Events 2:00 p.m. -3:00 p.m. Track 1: Navigating the Waters for Patients Co-Infected with HIV and HepC ACPE: 0106-9999-16-037-L02-P; 0106-9999-16-037-L02-T; (0.1 CEUs)
Presented by: Linda Spooner, PharmD, RPh, BCPS, FASHP; Professor of Pharmacy Practice, MCPHS University Upon completion of this activity, participants should be able to: 1. Provide updates in pharmacotherapy of HCV for this population. 2. Review of pertinent drugdrug interactions between HC pharmacotherapy and ART. 3. Discussion of patient counseling considerations for this population. Track 2: Medication Assisted Treatment for Opioid Use Disorder ACPE: 0106-9999-16-047-L01-P; 0106-9999-16-047-L01-T (0.1 CEUs)
Presented by: Kevin A. Sevarino, MD, PhD, Medical Director, Newington Mental Health, Connecticut V.A. Healthcare System and Medical Director, Provider Clinical Support System – Opioids (PCSS-O) Upon completion of this activity, participants should be able to: 1. Recognize the recent increase in those with opioid use disorder and the impact on public health. 2. Describe the significant role opioid prescribers have played in the current opioid epidemic. 3. List the medication options available to treat opioid use disorders, and identify their pros and cons. 4. Explain office-based opioid treatment and sources of ongoing education, including the PCSS-O and PCSSMAT programs. Track 3: Eye Care 101 for the Pharmacist ACPE: 0106-9999-16-038-L01-P; 0106-9999-16-038-L01-T (0.1 CEUs)
Presented by: Andrew McLeod, OD, MSc, FAAO; Director, Contact Lens Program, Assistant Professor, New
18
England College of Optometry, Boston Upon completion of this activity, participants should be able to: 1. Identify different types of contact lenses and recommended care products. 2. Describe multi-factorial dry eye disease and treatment options. 3. Explain ocular allergies and prescribing challenges. 4. Describe the interdisciplinary role between optometry and pharmacy. Track 4: Pepto Bowl: Student and Pharmacist Self-Care ACPE: 0106-9999-16-039-L04-P; 0106-9999-16-039-L04-T; (0.1 CEUs)
Facilitator: Jef Bratberg, PharmD, BCPS; Clinical Professor, University of Rhode Island School of Pharmacy Upon completion of this activity, participants should be able to: 1. Identify products (and active ingredients) routinely used for safe and effective use in self-care conditions. 2. Explain the efficacy, dosage, adverse effects, and administration of nonprescription medicines. 3. Counsel on non-pharmacologic measures for the treatment of common self-care ailments.
pharmacists working in various practice settings, including issues of product substitution and interchangeability. 4. Identify unresolved and emerging issues that complicate the safe integration of biosimilars into the US healthcare system. Track 2: Breaking the Back of the Beast: Successful Chronic Pain Management and Commonsensical Opioid Use ACPE: 0106-9999-16-041-L01-P; 0106-9999-16-041-L01-T; (0.1 CEUs) Application Based
Presented by: Michele Matthews, PharmD, CPE, BCACP; Associate Professor of Pharmacy Practice, MCPHS University and Clinical Pharmacy Specialist, Brigham & Women’s Hospital Upon completion of this activity, participants should be able to: 1. Analyze patient-specific information to determine the appropriateness of opioid therapy for the management of chronic pain. 2. Implement best practices for initiating, monitoring, and discontinuing chronic opioid therapy. 3. Design an individualized pain management plan in the setting of chronic pain that integrates both pharmacalogic and nonpharmacologic therapies.
3:10 p.m. - 4:10 p.m. Track 1: Opportunities and Challenges for Pharmacists with the Introduction of Biosimilars
Track 3: Management of Common Eye Diseases: Pharmacy Has an Important Role
ACPE: 0106-9999-16-040-L04-P; 0106-9999-16-040-L04-T; (0.1 CEUs)
ACPE: 0106-9999-16-042-L01-P; 0106-9999-16-042-L01-T; (0.1 CEUs)
Presented by: James G. Stevenson, PharmD, FASHP; Professor, Department of Clinical Pharmacy, University of Michigan College of Pharmacy
Presented by: Celia P. McDonnell, PharmD; Clinical Professor of Pharmacy, University of Rhode Island & Adjunct Associate Professor of Family Medicine, Alpert Medical Center, Brown University
Upon completion of this activity, participants should be able to: 1. Discuss the current status of biosimilars in the United States, including recent FDA guidance. 2. Summarize the European experience with biosimilars. 3. Identify clinical and regulatory implications of biosimilars for
You may attend any track. You do not have to stay in the same room for all 4 sessions.
compared to traditional 100unit/ml insulins. 2. Describe the pharmacokinetic, pharmacodynamics, and clinical properties of concentrated and newer insulin products. 3. Evaluate current and emerging insulin therapies such as biosimilar insulin and insulin delivery devices. 4. Utilizing a patient case, identify the role of concentrated and newer insulin products.
Upon completion of this activity, participants should be able to: 1. Explain the etiology and pathophysiology of glaucoma, macular degeneration, dry eye disease, and allergic conjunctivitis. 2. Compare the mechanism of action, efficacy, and safety of current and emerging drug therapies that target these common eye diseases. 3. Illustrate the appropriate use of over-the-counter and prescription products for the management of common eye diseases. 4. Identify modifications to medication regimens, diet, lifestyle, and environmental factors that support management of glaucoma, dry eye disease, macular degeneration, and allergic conjunctivitis. Track 4: The Rising Role of Digital Health in Patient Care: What Healthcare Professionals Need to Know
ACPE: 0106-9999-16-043-L04-P; 0106-9999-16-043-L04-T;(0.1 CEUs )
Presented by: Timothy Aungst, PharmD; Assistant Professor of Pharmacy Practice , MCPHS University, Worcester Upon completion of this activity, participants should be able to: 1. Explain how emerging technologies like Digital and Mobile Health impact today’s changing sphere of healthcare. 2. Recognize the importance of health information technologies in the daily practice of clinicians working with their patients and other members of the healthcare team. 3. Identify the impact new digital health tools have on chronic disease management for clinicians working with patients. 4. Identify current limitations and weaknesses of digital health for clinicians managing their patient’s care. 5. Identify what clinicians need to be aware of when recommending digital health tools to their patients. 4:20 p.m. -5:20 p.m. Track 1: New and Emerging Insulins for Diabetes
Track 2: Opioid-Induced Constipation - Prevention and Treatment Strategies ACPE: 0106-9999-16-045-L01-P; 0106-9999-16-045-L01-T; (0.1 CEUs)
Presented by: Trinh Pham, PharmD, BCOP; Clinical Professor, University of Connecticut School of Pharmacy Upon completion of this activity, participants should be able to: 1. Describe the epidemiology and etiology of opioid induced constipation (OIC). 2. Review the strategies to prevent OIC with nonpharmacologic and over the counter pharmacologic options. 3. Explain the emerging pharmacological approaches to the management of OIC including: lubiprostone, methylnatrexone and naloxegol. 4. Describe the precautions, contraindications, and adverse effects associated with the newer prescription agents to treat OIC. 5. Discuss the role of the pharmacist in identifying patients at risk for OIC and making recommendations to prevent or treat OIC . Track 3: Immunization Update for Immunizers 2016
ACPE: 0106-9999-16-046-L04-P; 0106-9999-16-046-L04-T; (0.1 CEUs)
Presented by: Todd Brown, RPh; Executive Director, MIPA, Vice Chair, Northeastern University Upon completion of this activity, participants should be able to: 1. Identify changes to the CDC immunization schedule for adults. 2. Utilize the current CDC immunization schedule for adults. 3. Explain changes to commercially available vaccines. 4. Describe research and recommendations to increase vaccination rates. Track 4: TED Talks Five New England pharmacy residents will be given the opportunity to present their residency research abstracts. Each presentation will be 10 minutes in length, providing a “nugget of knowledge” the residents have encountered in pharmacy practice. Title and objectives will be posted after the “Fab Five” have been selected. To learn more visit nepharmacists.org and click on Fab Five.
ACPE: 0106-9999-16-044-L01-P; 0106-9999-16-044-L01-T; (0.1 CEUs); Application Based
Presented by: Jennifer Goldman, PharmD, CDE, BC-ADM, BCCP; Professor of Pharmacy Practice, MCPHS-Boston; Clinical Pharmacist, Well Life, Peabody, MA Upon completion of this activity, participants should be able to: 1. Identify why there is a need for concentrated insulins
19
Certificate Program in Pharmacy-Based Cardiovascular Disease Risk Management--September 22, 2016 8:00 a.m. to 5:00 p.m. The goals of the certificate training program are to: • Educate pharmacists on current evidence-based treatment goals and clinical management recommendations for dyslipidemia and hypertension. • Familiarize pharmacists with important concepts related to healthful lifestyle changes that focus on cardiovascular disease prevention. • Introduce techniques and skills for encouraging patient adherence to prescribed therapies. • Ensure pharmacist proficiency in blood pressure measurement technique and point-of-care lipid testing. • Enhance pharmacist experience in applying elements of motivational interviewing with respect to medication adherence and lifestyle modifications. • This ACPE activity does not provide a certification in this topic but rather advanced professional training. The activity is conducted in two parts: a web-based self-study and a live training seminar. The live seminar will focus on these core areas: • A case-based approach to cardiovascular disease risk assessment and treatment decisions, managing special situations, treating hypertension in a patient with diabetes, and lifestyle modifications and motivational interviewing. • Skills assessments on blood pressure measurement technique and motivational interviewing. Participants will be conducting blood pressure assessments on other participants. • A discussion regarding the role of the pharmacist and existing business models for cardiovascular disease risk management services. Activity Completion Requirements The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of CPE. The self-study learning component of the APhA Pharmacy-Based Cardiovascular Disease Risk Management certificate training program is approved for 12 hours (1.2 CEUs) of continuing pharmacy education credit (UAN 0202-0000-15-001-H04-P; 0202-9999-15-001-H04-P). The live training seminar is approved for 8 hours (0.8 CEUs) of continuing pharmacy education credit (UAN 0202-0000-15-002-L04-P; 0202-9999-15-002-L04-P). Completion Information: A Certificate of Achievement is awarded to participants who successfully complete all activity requirements, which include the self-study component, live training seminar, and the injection technique assessment. Successful completion is defined as a score of 70% or better on both the self-study and live seminar assessments. Pharmacy-Based Cardiovascular Disease Risk Management is developed by the American Pharmacists Association. Faculty: Meghan Wilkosz, PharmD, Clinical Pharmacy Specialist at VA Connecticut Healthcare System
Registration Information Online Registration
Please go to www.nepharmacists.org to register. Deadline for online registration is September 15, 2016. Fax or Mail
Fax form with credit card information to 781-933-1109. Please make all checks payable to the New England Pharmacists Convention. Mail form to NE Convention, c/o MPhA., 500 W. Cummings Park, Suite 3475, Woburn, MA 01801. Please complete all portions of the registration form. If you register after September 15, there will be an additional $10 fee. Registration Questions
Please contact MPhA at 781-933-1107 or at info@masspharmacists.org Cancellations must be made in writing to MPhA. Registration cancellations received prior to 8/31/16 will be refunded less a $25 processing charge per registrant. Cancellations received after 8/31/16 will not be refunded. Continuing Education Information: In order to receive a statement of credit uploaded to CPE Monitor, participants must complete an evaluation and CE registration form, in addition to attending the program in its entirety.
Enjoy great speakers, networking and fun at New England’s premiere convention for pharmacists. 20
Continuing Education Credits: The Connecticut Pharmacists
Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Attendees can earn up to 11.5 hours (1.15 CEUs) of continuing education credit which includes 2 hours (0.2 CEUs) in pharmacy law. All learning activities are knowledge based unless otherwise noted.
To Register Online, please visit www.nepharmacists.org
Registration Form
Bundled CE Options
Convention Registration Rates
Member rates apply for members of CPA, MPhA (MA), NHPA, Pharmacy-Based Cardiovascular Disease Risk Management & Friday RIPA, VTPA, and MPARX. CE** Member $430.00 Non-Member $525.00 Full Convention*
(includes CE, Reception, Friday breakfast, lunch & exhibit hall) Member $189.00
Delivering Medication Therapy Management Services & Friday CE**
Member $430.00
Non-Member $239.00
The Pharmacist and Patient-Centered Diabetes Care & Friday CE* *
Member $430.00
Thursday Only*
(includes CE and Reception) Member $119.00
Non-Member $525.00 Non- Member $525.00
Deadlines for all Certificate program registration is August 31, 2016. All Bundled CE options include Friday CE offerings, breakfast, lunch, and Exhibit Hall.
Non-Member $130.00
**do not include reception or banquet
Friday Only*
(includes CE, breakfast, lunch & exhibit hall) Member $149.00
Non-Member $189.00
Member $379.00
Non- Member $429.00
Additional Offerings
Installation & Awards Banquet (includes Cocktail Reception with one free drink ticket) Student: $50.00 *Does not include Certificate Programs or Banquet Select Banquet: CPA $60.00 per person #___________ MPhA $60.00 per person #_________ Certificate Programs RIPA $120.00/couple #__________ $65.00/person________ NEW! Pharmacy-Based Cardiovascular Disease Risk Management Guest Friday Lunch & Exhibit Hall (does not include CE offerings) Member $379.00 Non- Member $429.00 $35.00 per person #_____ Delivering Medication Therapy Management Services Guest Name___________________________________
Total Amount: $
The Pharmacist and Patient-Centered Diabetes Care
Member $379.00
Non-Member $429.00
All Certificate Programs include breakfast, lunch and a break
Name: ______________________________________________________________________________________ Prefix
First
Middle Initial
Last
Mailing Address: __________________________________________________________________________ City: __________________________________________State: _______ Zip: _____________ Telephone: _____________________________________Email: _______________________________________ State Association & Member Number: ____________________________________________________________ Practice Setting_______________________________________________________________________________ Optional
Students Only: University/College___________________________________________________Year of Grad.______________ Currently Enrolled
Payment Method: Credit Card:
MC
VISA
AMEX
Check
(payable to New England Pharmacists Convention)
Credit Card #:__________________________________Security Code#: ________ Expiration Date: __________ Card Holders Name:__________________________________________________________________________ Signature:____________________________________________________ Date: __________________________ 21
Certificate Programs
®
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Pharmacist & Patient-Centered Diabetes Care Certificate Training Program September 22, 2016 8:00 a.m. to 5:00 p.m. The Pharmacist and Patient-Centered Diabetes Care Certificate Training Program is an intensive educational experience designed to equip pharmacists with the knowledge, skills, and confidence needed to provide effective, evidence-based diabetes care. Five self-study modules provide comprehensive instruction in current diabetes concepts and standards of care. The live seminar incorporates case studies and hands-on skills training focused on the situations most likely to be encountered—as well as the services most needed—in community and ambulatory care practice settings. Participants will gain experience evaluating and adjusting drug therapy regimens for patients with type 1 and type 2 diabetes, counseling patients about lifestyle interventions, analyzing and interpreting self-monitoring of blood glucose results, and assessing the overall health status of patients to identify needed monitoring and interventions. The goals of the certificate training program are to: • Provide comprehensive instruction in current standards of care for patients with diabetes. • Increase pharmacists’ confidence in serving as the drug therapy expert on the diabetes health care team.
• Refresh pharmacists’ knowledge of the pathophysiology of diabetes and the acute and long‐term complications of the disease. • Familiarize pharmacists with important concepts in nutrition, exercise, and weight control that contribute to optimal diabetes care. • Provide training on the use of diabetes-related devices and physical assessments involved with optimal diabetes care. • Describe business opportunites and roles for pharmacists in improving health outcomes for patients with diabetes. This entire certificate training program will offer you the opportunity to earn up to 23 hours (2.3 CEUs) of continuing pharmacy education credit. SEMINAR AGENDA: Welcome & Introduction Comprehensive Care Needs Intensifying Drug Therapy Nutrition Counseling Insulin Therapy Hands-On Assessments Special Situations in Diabetes Management Next Steps and Resources Closing Remarks
Delivering Medication Therapy Management Services Delivering Medication Therapy Management Services is an innovative and interactive certificate training program that explores the pharmacist’s role in providing MTM services to patients. Pharmacists have a tremendous opportunity to receive reimbursement for monitoring and improving medication use in patients with complex medication regimens. This practice-based activity teaches pharmacists the essential skills necessary to become a successful MTM practitioner. The certificate training program will enhance pharmacists’ clinical expertise in evaluating complicated medication regimens, identifying medication-related problems, and making recommendations to patients, caregivers, and health care professionals. T The certificate training program is conducted in three parts: a self-study activity and pre-seminar exercise, a live interactive training seminar, and a post-seminar exercise. The goals of the certificate training program are to: • Advance public health and patient care through improved medication use. • Provide training to enhance pharmacists’ ability to effectively provide MTM services.
22
Faculty: Lisa DeGennaro Pharm D, CDE; Assistant Professor, Department of Pharmacy Practice, University of Saint Joseph, West Hartford, CT Kristen Rychalsky, PharmD, BCPS; Clinical Pharmacy Specialist, Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT Successful completion of the live seminar component involves passing the final exam with a grade of 70% or higher and demonstrating competency in blood pressure testing, selfinjection techniques, diabetic foot exam, and blood glucose testing. Successful completion of these components will result in 8 contact hours of continuing pharmacy education (0.8 CEUs) ACPE UAN: 0202-9999-14-166-L04-P Successful completion of the self-study component involves passing the self-study assessment with a grade of 70% or higher and will result in 15.0 contact hours of continuing pharmacy education credits (1.5 CEUs) ACPE UAN: 0202-9999-14-165-L04-P The Pharmacist & Patient-Centered Diabetes Care was developed by the American Pharmacists Association.
• Motivate increased numbers of pharmacists to establish MTM services. • Communicate benchmark practices for providing MTM services. SEMINAR AGENDA: The Patient Interview Pre-Seminar Case Review: Communication Barriers Case Study: William Documentation The Medication Therapy Review Case Study: Carl Setting Therapeutic Goals Medication-Related Action Plan Standardized Case Review: Toni Recommendation to Other HealthCare Professionals Cultural Sensitivity The Senior Patient Case Study: Donna Staying Current Standardized Case Review: Toni Implementation SWOT Analysis Setting Business Goals and Recruiting Patients Billing Concepts, CPT Coding, and Measuring Outcomes Take Home Points and Post-Seminar Assignment Patient Case Assessment Discussion
September 22, 2016
8:00 a.m. to 5:00 p.m.
Evaluation and Adjournmen This entire certificate training program will offer you the opportunity to earn up to 21 hours (2.1 CEUs) of ACPE-accredited continuing pharmacy education credit. Faculty: Susan Holden, Pharm.D., Clinical Pharmacy Specialist , VA Boston Healthcare System, West Roxbury, MA Successful completion of the self-study component will result in 10 contact hours of continuing pharmacy education credit (1.0 CEUs). ACPE UAN: 0202-0000-14-H04-P; 0202-9999-14-158-H04-P Successful completion of the live seminar component will result in 8 contact hours (0.8 CEU) of continuing pharmacy education credit (0.8 CEUs). ACPE UAN: 0202-0000-14-159-L04-P; 0202-9999-14-159-L04-P Successful completion of the post-seminar exercise will result in 3.0 contact hours of continuing pharmacy education credit (0.3 CEUs). ACPE UAN: 0202-0000-14-159-L04-P; 0202-9999-14-160-H04-P
2015 Recipients of the “Bowl of Hygeia” Award
Dan McConaghy Alabama
Tom Van Hassel Arizona
Nicki Hilliard Arkansas
Robert Shmaeff California
Sherman Gershman Connecticut
Kevin Musto Delaware
Fritz Hayes Florida
Ron Stephens Georgia
Kerri Okamura Hawaii
Steven Bandy Illinois
Jane Krause Indiana
Richard Hartig Iowa
Robert Nyquist Kansas
Larry Stovall Kentucky
Lloyd Duplantis Louisiana
Kenneth McCall Maine
Butch Henderson Maryland
Paul Jeffrey Massachusetts
Derek Quinn Michigan
Jenny Houglum Minnesota
Robert Wilbanks Mississippi
Richard Logan Missouri
Gayle Hudgins Montana
Heather Mooney Nevada
Richard Crowe New Hampshire
Edward McGinley New Jersey
Amy Bachyrycz New Mexico
Benjamin Gruda New York
David Moody North Carolina
Kevin Oberlander North Dakota
Danny Bentley Ohio
Gordon Richards, Jr. Oklahoma
Ann Zweber Oregon
Thomas Mattei Pennsylvania
Deborah Newell Rhode Island
Sharm Steadman South Carolina
Renee Sutton South Dakota
Mac Wilhoit Tennessee
Jim Cousineau Texas
Marvin Orrock Utah
John Beckner Virginia
Gregory Hovander Washington
Terri Smith Moore Washington DC
David Flynn West Virginia
Brian Jensen Wisconsin
Randy Harrop Wyoming
The “Bowl of Hygeia”
The Bowl of Hygeia award program was originally developed by the A. H. Robins Company to recognize pharmacists across the nation for outstanding service to their communities. Selected through their respective professional pharmacy associations, each of these dedicated individuals has made uniquely personal contributions to a strong, healthy community. We offer our congratulations and thanks for their high example. The American Pharmacists Association Foundation, the National Alliance of State Pharmacy Associations and the state pharmacy associations have assumed responsibility for continuing this prestigious recognition program. All former recipients are encouraged to maintain their linkage to the Bowl of Hygeia by emailing current contact information to awards@naspa.us. The Bowl of Hygeia is on display in the APhA Awards Gallery located in Washington, DC.
23
Boehringer Ingelheim is proud to be the Premier Supporter of the Bowl of Hygeia program.
Feature Important Updates for Influenza Vaccinations: 2016-17 by Caroline Liang, PharmD Candidate 2017 and Jennifer Girrotto, PharmD
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) met on February 24, 2016 and June 22-23, 2016 to discuss, vote, and update its recommendations for the 2016-2017 influenza season. This article will summarize important changes for pharmacists regarding influenza vaccination for this upcoming season. All vaccines will contain an A/California/7/2009 (H1N1)pdm09like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, and a B/Brisbane/60/2008-like virus.1 Additionally, quadrivalent vaccines will also contain a B/Phuket/3073/2013-like virus.1 This differs from the previous season’s vaccine products where trivalent vaccines contained a B/Phuket/3073/2013like virus and quadrivalent vaccines contained a B/ Brisbane/60/2008-like virus.1-2 ACIP has clarified that healthcare providers should offer influenza vaccination by the end of October if possible to all patients aged 6 months and older without contraindications to best ensure vaccination prior to the onset of influenza activity.3 Influenza vaccination should continue as long as unexpired vaccine is available and influenza viruses are circulating in the community,3 which is often until March or April.4 Both trivalent and quadrivalent vaccines will be available this season. One significant difference in this year’s product recommendations is that ACIP has voted to not recommend use of the live attenuated intranasal influenza vaccine in any population this season.5 This significant change is in light of the evidence for the poor effectiveness of the live intranasal vaccine in the US over the last three influenza seasons.5 In addition, the latest vaccines effectiveness data indicates that the inactivated influenza vaccine shot is more effective than the live intranasal influenza vaccine against influenza A(H1N1)pdm09 and that there is uncertainty about the effectiveness of the live intranasal influenza 24
vaccine against A(H3N2) and B viruses.5 Specific influenza vaccines available for the 2016-2017 season are listed in Table 1. There have been a few new vaccines approved since the beginning of the last influenza season. First, Flucelvax Quadrivalent (Seqirus) was recently approved in May 2016.6 Flucelvax Quadrivalent is the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine approved for patients aged 4 years and older.7-8 The newly approved vaccine is an evolution of the trivalent Flucelvax vaccine from the former Novartis Vaccines and Diagnostics, now merged with bioCSL to form Seqirus.7 Due to the identical manufacturing process and overlapping compositions between the quadrivalent and trivalent vaccines, clinical efficacy and safety data from clinical trials with Flucelvax are relevant to Flucelvax Quadrivalent.7-8 Flucelvax was shown to be efficacious against influenza caused by vaccine-like strains (83.8%) and by all circulating influenza strains (69.5%) in clinical studies of adults aged 18-49 years.6 Further, it was shown to be well tolerated and immunogenic against influenza in adults aged 18 years or older and children aged 4-17 in two separate randomized, double-blind, controlled studies in the US.6-8 Another new vaccine is Fluad (Seqirus), which was approved in November 2015 for patients aged 65 years and older.5, 9 Fluad is the first adjuvanted inactivated influenza vaccine approved in the US.5, 9 The vaccine is formulated with the adjuvant MF59, an oil-in-water emulsion of squalene oil.9 MF59 was added in order to try to ensure immunogenicity in the elderly, where there is often a concern with their ability to mount an immune response to vaccination.9 Fluad was evaluated against a US licensed, non-adjuvanted trivalent influenza vaccine to compare immunogenicity and safety in a multicenter Phase III clinical trial conducted in the US and internationally with over 7000 patients.9-10 The study found that Fluad was non-inferior to the comparator vaccine for seroconversion rates and geometric mean titers and had
Pharmacy Journal of New England • Summer 2016
significantly higher influenza antibody titers for all three vaccine strains in patients aged 65 years or older.10 Fluad has been available internationally for many years, as the vaccine was first approved for use in Italy in 1997, and is approved in over 30 countries.10-11 In addition to currently approved products, some vaccines may have potential upcoming licensures or approval modifications that will also be acceptable options as influenza products for the appropriate age groups if licensed. These vaccines include Flublok Quadrivalent (Protein Sciences) as a potential new approval and Flulaval Quadrivalent (ID Biomedical Corporation of Quebec) seeking an age approval modification.5 Flublok Quadrivalent, similar to the currently approved Flublock, is a recombinant influenza vaccine and is also seeking approval for patients aged 18 years and older.5, 12 The only significant difference between the two is that the potentially approved quadrivalent will provide protection against 4 rather than 3 strains. Flulaval Quadrivalent is an inactivated quadrivalent influenza vaccine currently approved for patients aged 3 years and older, and is seeking approval for patients aged 6 months or older.5, 13 Not only have there been changes to influenza vaccine products for the upcoming year, but also ACIP has voted to make specific changes to recommendations for the use of influenza vaccines in patients with egg allergies. These changes are the result of the rarity of severe adverse reactions to the influenza vaccine, such as anaphylaxis, and that when they do occur, it may not be within 30 minutes after vaccination.2 Specifically, the recommendations voted on for the 2016-2017 season are that patients with an egg allergy history should receive any influenza vaccine that would be otherwise appropriate.2 This is a significant change from prior years’ recommendations where ACIP had only recommended the recombinant trivalent inactivated influenza vaccine or inactivated influenza vaccine in these patients.2-3 Although any appropriate vaccine may be administered, the types of services needed available when vaccinating these patients are further clarified. First, in cases where patients have only experienced only hives after egg exposure, no unique recommendations are in place, although personnel and equipment for rapid recognition and treatment of allergic reactions should be available for all patients regardless of
allergy history.3 Patients with a more severe history of egg allergy (i.e. those who have experienced symptoms other than hives after egg exposure such as angioedema, respiratory distress, lightheadedness, or recurrent emesis) or who required epinephrine or another emergency medical intervention should have the vaccine administered in a medical setting where a healthcare provider with experience in recognizing and managing severe allergic reactions is immediately available.3 Importantly, ACIP has also voted to remove other restrictions for patients with egg allergies. First, a 30-minute post-vaccination observation period is no longer recommended, although all patients should still generally be observed after vaccination to ensure that patients do not have syncopal episodes.3 The ACIP also removed its previous recommendations of confirming egg allergies in patients and consulting with a physician with expertise in the management of allergic conditions before vaccination.2-3 In summary, the ACIP has voted to make numerous changes to its recommendations for the 2016-2017 influenza season, which should be followed once they are formally published in the CDC Morbidity and Mortality Weekly Report (often mid-August). Specifically, the recommendations that have been voted on include: healthcare providers should offer influenza vaccination by the end of October and the live attenuated intranasal influenza vaccine is not recommended in any population this season. All vaccines will contain an A/California/7/2009 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, and a B/Brisbane/60/2008like virus and quadrivalent vaccines will contain an additional B/Phuket/3073/2013-like virus. The ACIP also voted to recommend that patients with an egg allergy history should receive any influenza vaccine that is otherwise appropriate. Patients who experienced only hives after egg exposure have no unique recommendations while patients with a more severe history of egg allergy or who required emergency medical interventions should have the vaccine administered in a medical setting with a healthcare provider experienced at recognizing and managing severe allergic reactions immediately available.
25
Feature
continued
Vaccine Category
Brand Name (Manufacturer)
Recommended Ages
Dose
IIV3, instramuscular
Afluria (bioCSL)
> 9 years*
0.5 mL
IIV3, instramuscular
Fluad (Seqirus)
> 65 years
0.5 mL
IIV3, instramuscular
Flucelvax (Seqirus)
> 18 years
0.5 mL
IIV3, instramuscular
Fluvirin (Seqirus)
> 4 years
0.5 mL
IIV3, instramuscular
Fluzone (Sanofi Pasteur)
6 - 35 months
0.25 mL
IIV3, instramuscular
Fluzone (Sanofi Pasteur)
> 36 months
0.5 mL
IIV3, instramuscular
Fluzone High-Dose (Sanofi Pasteur)
> 65 years
0.5 mL
RIV3, instramuscular
Flublok (Protein Sciences)
> 18 years
0.5 mL
IIV4, intramuscular
Fluarix Quadrivalent (Glaxo Smith Kline)
> 3 years
0.5 mL
IIV4, intramuscular
Fluzone Quadrivalent (Sanofi Pasteur)
6 - 35 months
0.25 mL
IIV4, intramuscular
Fluzone Quadrivalent (Sanofi Pasteur)
> 36 months
0.5 mL
IIV4, intramuscular
FluLaval Quadrivalent > 3 years (ID Biomedical Corporation of Quebec)
0.5 mL
IIV4, intramuscular
Flucelvax Quadrivalent (Seqirus)
> 4 years
0.5 mL
IIV4, intradermal
Fluzone Intradermal Quadrivalent (Sanofi Pasteur)
18 years - 64 years
0.1 mL
LAIV4, intranasal
FluMist Quadrivalent (MedImmune)
2 years - 49 years
0.1 mL in each nostril
Table 1. Available vaccines for the 2016-2017 influenza vaccine season. Abbreviations: IIV3 = trivalent inactivated influenza vaccine; RIV3 = recombinant, trivalent inactivated influenza vaccine; IIV4 = qaudrivalent inactivated influenza vaccine; LAIV4 = quadrivalent live, attenuated influenza vaccine. *Age indication as per package insert is ≥ 5 years; however, the ACIP recommends that Afluria not be used in children aged 6 months through 8 years due to increased risks of febrile reactions noted in this age group with bioCSL’s 2010 Southern Hemisphere IIV32
References:
1 Influenza virus vaccine for the 2016-2017 season. Food and Drug Administration website. http://www.fda.gov/BiologicsBloodVaccines/uidanceComplianceRegulatoryInformation/Post-MarketActivities/LotReleases/ucm504884. htm. Updated June 3, 2016. Accessed June 23, 2016. 2. Grohskopf LA et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunizations Practices, United States, 201516 influenza season. Centers for Disease Control and Prevention website. http://www. cdc.gov/mmwr/preview/mmwrhtml/mm6430a3.htm. Published Aug 7, 2015. Accessed June 23, 2016. 3. Grohskopf L. Proposed recommendations 2016-17 influenza season. Presented at the Meeting of the Advisory Committee on Immunization Practices; February 24, 2016; Atlanta, Georgia. 4. What you should know for the 2015-2016 influenza season. Food and Drug Administration website. http://www.cdc.gov/flu/about/season/flu-season-2015-2016. htm. Updated May 26, 2016. Accessed June 23, 2016. 5. Grohskopf L. Proposed recommendations summary. Presented at the Meeting of the Advisory Committee on Immunization Practices; June 22, 2016; Atlanta, Georgia.
8. Ernst D. Flucelvax Quadrivalent gets FDA approval. MPR website. http://www.empr. com/news/flucelvax-quadrivalent-gets-fda-approval/article/498552/. Published May 24, 2016. Accessed June 23, 2016. 9. FDA approves first seasonal influenza vaccine containing an adjuvant. Food and Drug Administration website. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm474295.htm. Updated Nov 24, 2015. Accessed June 23, 2016. 10. Ernst D. FDA committee votes yes on new flu vaccine for elderly. MPR website. http://www.empr.com/news/fda-committee-votes-yes-on-new-flu-vaccine-for-elderly/article/438730/. Published Sept 15, 2015. Accessed June 23, 2016. 11. About Fluad. Seqirus website. http://flu.seqirus.com/fluad/about-fluad.html. Updated March 2, 2016. Accesed June 23, 2016.
6. FLUCELVAX QUADRIVALENT (influenza vaccine) [package insert]. Seqirus
12. Flublok. Food and Drug Administration website. http://www.fda.gov/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm335836.htm. Updated July 2, 2015. Accessed June 23, 2016.
7. Seqirus receives FDA approval for FLUCELVAX QUADRIVALENTTM (influenza vaccine)
13. FluLaval Quadrivalent. Food and Drug Administration website. http://www.fda. gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm366061.htm. Updated Feb 25, 2016. Accessed June 23, 2016.
Vaccines and Diagnostics, Inc., Cambridge, MA; May 2016. http://flu.seqirus.com/files/ us_package_insert_flucelvax.pdf. Accessed June 23, 2016.
26
for people four years of age and older. PR Newswire website. http://www.prnewswire. com/news-releases/seqirus-receives-fda-approval-for-flucelvax-quadrivalent-influenza-vaccine-for-people-four-years-of-age-and-older-300273578.html. Published May 23, 2016. Accessed June 23, 2016.
Pharmacy Marketing Group
Pharmacy Journal of New England • Summer 2016
Rx and the Law By: Don R. McGuire Jr., R.Ph, JD
This series, Pharmacy and the Law, is presented by Pharmacists Mutual Insurance Company and your State Pharmacy Association through Pharmacy Marketing Group, Inc., a company dedicated to providing quality products and services to the pharmacy community.
Certificates of Insurance Joan is leasing a new building for her expanding pharmacy practice. As part of her lease, she must provide a certificate of insurance to her landlord. The landlord is insisting on a number of provisions that must be included on the certificate. However, her insurance company is unwilling to provide the certificate as required by the landlord. Joan is unhappy and stressed at being caught in the middle of this tug of war. A certificate of insurance is a document issued by an insurance company that provides evidence of property and/or casualty insurance coverage. This certificate is evidence for Joan’s landlord that she has coverage on her property and on other items required under the lease. The trend has been that landlords, vendors, customers, and others who have a contractual relationship with the insured business want additional provisions included on the certificate. Examples of these provisions include longer notice periods for policy cancellation, statement that coverage can’t be voided by the insured’s actions, or statements that the policy coverage meets the requirements of the contract. This is where the tug of war begins. The certificate is only evidence that insurance coverage exists. It is not an insurance policy. The certificate cannot change the policy or guarantee compliance with a contract. At least 16 states have specific laws that do not allow the insurance companies to add these sorts of provisions to the certificate. Numerous other states have implemented this prohibition through issuance of bulletins by the insurance commissioner. Here are two examples. Indiana’s law became effective in 2013. The law specifically states that a certificate does not amend, extend or alter the coverage provided by the policy referenced. It also states that the certificate cannot grants rights to a person that are
not contained in the policy, such as an extended notice period. Massachusetts has a very similar law that was passed in 2015. In addition to what Indiana’s law says, Massachusetts also says that the certificate shall not be construed as an insurance policy. Both states’ laws provide that it is a violation of the law to knowingly prepare, issue, request or require the issuance of a certificate contrary to the law. In both states, the insurance commissioner can enforce the law with a cease and desist order and the imposition of a fine (up to $500 in Massachusetts and up to $1,000 in Indiana). In many states, the certificate of insurance is a filed form. This means that the insurance company must have the certificate form filed with and approved by the Department of Insurance prior to using it. In these states, the insurance company is not allowed to deviate from the state-approved certificate. These laws and regulations are what put Joan in the middle of the tug of war. The landlord or other party is trying to modify the insurance policy issued to Joan through changes on the certificate. The policies themselves are also state-approved forms and cannot be changed arbitrarily. That may be why they are attempting to make the changes via the certificate. That is why Joan’s insurance company is reluctant to change the policy or the certificate of insurance. In many jurisdictions, it is a violation of the law for the insurance company to do so. In the states with laws specifically addressing certificates, Joan or the landlord could also be in violation of the law and fined accordingly for asking or requiring that the changes be made. In these situations, the insurance company is not just trying to be difficult. They are trying to comply with the law. You should ask your insurance company for an explanation as to why the requested changes can’t be made. This can then be passed on to the landlord or other requesting party.
27
Pharmacy Marketing Group
Financial Forum Will You Avoid These Estate Planning Mistakes? Too many wealthy households commit these common blunders Many people plan their estates diligently, with input from legal, tax, and financial professionals. Others plan earnestly, but make mistakes that can potentially affect both the transfer and destiny of family wealth. Here are some common and not-so-common errors to avoid. Doing it all yourself. While you could write your own will or create a will or trust from a template, it can be risky to do so. Sometimes simplicity has a price. Look at the example of Warren Burger. The former Chief Justice of the United States wrote his own will, and it was just 176 words long. It proved flawed – after he died in 1995, his heirs wound up paying over $450,000 in estate taxes and other fees, costs that likely could have been avoided with a lengthier and less informal will containing appropriate language.1 Failing to update your will or trust after a life event. Relatively few estate plans are reviewed over time. Any life event should prompt you to review your will, trust, or other estate planning documents. So should a life event affecting one of your beneficiaries. Appointing a co-trustee. Trust administration is not for everyone. Some people lack the interest, the time, or the understanding it requires, and others balk at the responsibility and potential liability involved. A co-trustee also introduces the potential for conflict. Being too vague with your heirs about your estate plan. While you may not want to explicitly reveal who will get what prior to your passing, your heirs should have an understanding of the purpose and intentions at the heart of your estate planning. If you want to distribute more of your wealth to one child than another, write a letter to be presented after your death that explains your reasoning. Make a list of which heirs will receive particular collectibles or heirlooms. If your family has some issues, this may go a long way toward reducing squabbles and the possibility of legal costs eating up some of this or that heir’s inheritance. 28
continued
Failing to consider what will happen if you & your partner are unmarried. The “marriage penalty” affecting joint filers aside, married couples receive distinct federal tax breaks in this country – estate tax breaks among them. This year, the lifetime gift and estate tax exclusion amount is $5.45 million for an individual, but $10.9 million for a married couple.1,2 If you live together and you are not married, it is worth considering how your unmarried status might affect your estate planning with regard to federal and state taxes. As Forbes mentioned last year, federal and state taxes claimed more than more than $15 million of the $35 million estate of Oscar-winning actor Phillip Seymour Hoffman. He left 100% of his estate to his longtime partner, and since they had never married, she could not qualify for the marriage exemption on inherited assets. While the individual lifetime gift and estate tax exclusion protected a relatively small portion of Hoffman’s estate from death taxes, the much larger remainder was taxed at rates of up to 40% rather than being passed tax-free. Hoffman also lived in New York, a state which levies a 16% estate tax for non-spouses once estates exceed $1 million.1 Leaving a trust unfunded (or underfunded). Through a simple, one-sentence title change, a married couple can fund a revocable trust with their primary residence. As an example, if a couple retitles their home from “Heather and Michael Smith, Joint Tenants with Rights of Survivorship” to “Heather and Michael Smith, Trustees of the Smith Revocable Trust dated (month)(day), (year)”. They are free to retitle myriad other assets in the trust’s name.1 Ignoring a caregiver with ulterior motives. Very few people consider this possibility when creating a will or trust, but it does happen. A caregiver harboring a hidden agenda may exploit a loved one to the point where he or she revises estate planning documents for the caregiver’s financial benefit. The best estate plans are clear in their language, clear in their intentions, and updated as life events demand. They are overseen through the years with care and scrutiny, reflecting the magnitude of the transfer of significant wealth. Citations. 1 - raymondjames.com/pointofview/seven_estate_planning_ mistakes_to_avoid [10/16/15] 2 - fool.com/retirement/general/2015/12/11/estate-planning-in2016-heres-what-you-need-to-kno.aspx [12/11/15]
From the Colleges
Pharmacy Journal of New England • Summer 2016
University of Connecticut School of Pharmacy UConn Professor Calls for Limiting Antibiotic Use in Farm Animals By: Colin Poitras In a major position statement released this month in the journal Pharmacotherapy, the Society of Infectious Disease Pharmacists is calling for significant changes in the way in which antibiotics are given to agricultural Michael Nailor animals and how antibiotics and antifungals are used on plants. The panel that crafted the statement was led by Michael Nailor, an associate clinical professor in the UConn School of Pharmacy and at Hartford Hospital Department of Pharmacy. Nailor recently elaborated on this important issue for UConn Today. Why are antibiotics being given to agricultural animals? In 1950, a large study found that adding antibiotics to livestock feed accelerated animal growth rates. The practice swept through the industry, and now about 80 percent of all antibiotics consumed in the United States are consumed by agricultural animals. These antibiotics are sold without a prescription, and in almost all cases without the involvement of a veterinarian. Does this result in increased meat and milk production in the United States? In the 1950s it did, but there is no compelling data that it still has the same effects, given contemporary agricultural methods for breeding, feeding, and general care. That is something that needs to be further explored so we can determine the benefits versus the known risks of continuing this practice. It sounds like the benefits are uncertain. What are the risks?
The FDA, USDA, and CDC all testified before Congress that the routine use of antibiotics in healthy agricultural animals was a major cause of antibiotic resistance in humans. Approximately 2 million illnesses and 23,000 human deaths annually are directly attributable to antibiotic resistance, and no matter how much effort is spent to decrease antibiotic overuse by primary care physicians and in hospitals, we cannot curtail this rising epidemic without controlling antibiotic use in agricultural animals. Remember that agricultural animals can infect people through bacteria on under-cooked meats and by infecting farm workers, butchers, grocers, or consumers, who then transmit the disease to others. Disease can also be transmitted through insects that act as carriers. It is also a risky proposition for the animals themselves. If antibiotics are being routinely given to animals, their infections are more likely to be lethal because the bacteria are likely resistant to standard treatment. What does the position statement recommend? The national panel is made up of pharmacists involved in antimicrobial stewardship programs who help physicians select antibiotic choices that lower the risk of antibiotic resistance. We recommend sensible steps that can bend the curve of antibiotic resistance. First, we would like to see whether the effects seen with antibiotic use and animal growth in 1950 are still occurring today. With changes in breeding, feeding, and other techniques, antibiotics may not be producing any benefits but still causing harm. Second, we would like to limit the use of any antibiotic classes that are currently used in humans to agricultural animals that are actually sick, as verified by a veterinarian. Third, we would support funding of alternative methods to enhance animal growth without the use of antibiotics or other means that are known to risk human health. Finally, we want research to be conducted assessing the use of antibiotics and antifungal drugs on plants. There is increasing use of antifungal drugs that are used in humans to treat grass, bushes, and plants, increasing the risk that resistance will develop. We don’t know about the extent of that problem, but it is better to get out ahead of it than to wait for it to become a crisis, like we have with antibacterial resistance. Ultimately, the panel wants our elected officials to recognize the extent of this problem and 29
From the Colleges
continued
help devise prudent solutions that protect human and animal health. As an associate clinical professor of pharmacy practice, you have a special type of faculty position, tell me more about it. A majority of the faculty in UConn’s Department of Pharmacy Practice are embedded in hospitals, health systems, and clinics throughout Connecticut. We provide direct patient care, and teach students in a real world, hands-on environment how to provide competent, compassionate care. I have a co-funded position between the Department of Pharmacy Practice and Hartford Hospital’s Department of Pharmacy, where I have two primary jobs. The first is to direct antimicrobial stewardship practices throughout Hartford Healthcare. This entails devising strategies that are used by our network of providers to use antimicrobials in the most efficient manner. The second major aspect of my position involves performing antimicrobial stewardship at the local level, by helping our providers evaluate patients possibly infected at the hospital and optimizing antibiotics for individual patients. Often these individual patients are infected with the most resistant isolates we encounter at the hospital. That is why this topic is personally very important to me. Seeing patients with no viable antibiotics to treat a serious infection, or someone who has to take an antibiotic with serious adverse effects because it is the only one available is heartbreaking, and I work every day to ensure that the antibiotics we have today last as long as possible and can benefit those who need it the most. In this way, I support UConn’s Land Grant charge to give back to the people of Connecticut and our Carnegie Engaged University designation. My scholarship is centered around tracking outcomes (health of patients, costs of care, and development of resistance) of our antimicrobial stewardship efforts within the hospital and health system. These activities support not only UConn’s charge to further scientific inquiry and disseminate it beyond Connecticut, but they also directly facilitate my work at the bedside, informing us of what works and what doesn’t work. In addition, I am a director of a postgraduate training program for pharmacists to develop their antimicrobial stewardship clinical and research skills. All of these programs come together with a terrific group of 30
collaborators both at the hospital and at UConn, including Dr. Jack Ross, chief of infectious diseases at Hartford Hospital; David Nicolau and Joseph Kuti from the Center for AntiInfective Research and Development at Hartford Hospital, which focuses on optimizing antimicrobial use; and Professors Amy Anderson and Dennis Wright in UConn’s Department of Pharmaceutical Sciences, who are working on developing a new class of antibiotics, so we can try and stay one step ahead of bacteria. More information about what the federal government and different national agencies are doing to monitor the use of antibiotics in food-producing animals can be found on these sites: Federation of Animal Science Societies (FASS) Policy Statement on Preserving the Benefits of Antibiotics for People and Animals FDA Biannual Progress Report on Judicious Use of Antimicrobials in Food-producing Animals USDA Antimicrobial Resistance Action Plan White House National Action Plan for Combating AntibioticResistant Bacteria
Did You Know? That the Connecticut Pharmacists Association offers a 2-Week Online Course for CT Law? www.ctpharmacists.org
Pharmacy Journal of New England • Summer 2016
Husson University School of Pharmacy
Study Finds Prescription Monitoring Program Underutilized in Maine A team of researchers, including Husson University School of Pharmacy Associate Professor and Psychiatric Pharmacist Stephanie Nichols, PharmD, BCPS, BCPP published a study in the Journal of Studies on Alcohol and Drugs that has profound implications for the opioid addiction crisis in Maine.
allows providers to see whether a patient has a history of drug-related arrests, according to Nichols. “We have resources to help tackle the opioid epidemic,” she said, “but we’re underusing them.” In an encouraging sign, though, prescriptions for oxycodone and hydrocodone were lower in 2014, while prescriptions for buprenorphine were up sharply. Buprenorphine is an opioid, but it’s typically used to treat opioid addiction. “I think that’s a positive trend, because we interpret that as an increase in treatment of people with an Opioid Use Disorder,” Nichols said.
Stephanie Nichols, PharmD, BCPS, BCPP
According to the study, even though the misuse and diversion of prescription pain medications remains a major public health problem in Maine, a key program to help monitor and prevent opioid abuse is being underused. Most U.S. states have established prescription-monitoring programs (PMPs) -- electronic databases that track prescriptions for opioids and other controlled substances. Healthcare providers can use the programs to identify possible cases of prescription drug misuse, and help patients get treatment for addiction if needed. While Maine has had a PMP since 2004, Nichols’ team found that in 2014, many pharmacists were not using it. Of 275 pharmacists surveyed, only 56 percent said they were using the program. Doctors and other healthcare providers use the system, but it’s still important for pharmacists to be linked in, too, according to Nichols. “Often, the pharmacist is the ‘last line of defense,’ for patient safety,” she said. Based on the state’s PMP, opioids were prescribed to 22 percent of Maine residents in 2014 -- enough to supply every man, woman and child in the state with a 16-day supply. That figure is down slightly from 2010, Nichols said. “But it’s still a very large number,” she added. Beside a PMP, Maine also has a diversion alert program that
Still, she added, more can be done. That includes getting healthcare providers and pharmacists on board with existing programs and increasing the accessibility and usability of said programs. The study also revealed another troubling trend associated with opioid addiction in Maine. In 2014, a high percentage of women in their 80s -- 38 percent -- had prescriptions for opioids. “That’s very concerning,” said Dr. Nichols. For one, she explained, elderly people have a higher rate of respiratory conditions, which makes them more susceptible to an accidental opioid overdose. What’s more, the study found, women in their 80s were also commonly prescribed sedatives known as benzodiazepines. “If one of those medications were combined with an opioid, that would also raise the risk of a potentially fatal overdose,” says Nichols. Prescription opioids include medications like hydrocodone (Vicodin), oxycodone (OxyContin, Percocet), codeine, and morphine. According to the U.S. National Institute on Drug Abuse, an estimated 52 million Americans have ever abused a prescription drug -- and opioid painkillers top the list. Members of Nichols team who participated in this study included Dr. Brian Piper. Piper was the lead investigator on the study. He is currently a visiting assistant professor of psychology and neuroscience at Bowdoin. The co-authors of the study were Dr. Sarah Martin and Dr. Robert Baker. Sarah L. Martin, PhD, is an assistant 31
From the Colleges
continued
professor while Robert P. Baker, PharmD, is a manager of quality assurance in experiential education and an associate professor of pharmacy practice. Both are faculty members at the Husson University School of Pharmacy. Other researchers who participated in this study included: Kenneth L. McCall, PharmD, CGP, an associate professor and residency director at the University of New England; Clare E. Desrosiers, MSW, executive director for Diversion Alert, a program sponsored by the Substance Abuse Prevention Coalition in Aroostook County, Maine; John Lipovsky, past coordinator of the prescription monitoring program with the Maine Office of Substance Abuse and Mental Health Services; and Matthew A. Rodney, PharmD, a Husson University School of Pharmacy graduate. Founded in 2006, the Husson University School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE). The School graduated its first class with Doctorate of Pharmacy (PharmD) degrees in May 2013.
contemporary pharmacy education is highly valued. The School of Pharmacy has been able to attract nationally renowned educators with expertise in alcohol research, wound healing, and national board certification in the specialty areas of pharmacotherapy. For more than 100 years, Husson University has prepared future leaders to handle the challenges of tomorrow through innovative undergraduate and graduate degrees. With a commitment to delivering affordable classroom, online and experiential learning opportunities, Husson University has come to represent superior value in higher education. Our Bangor campus and off-campus satellite education centers in Southern Maine, Wells and Northern Maine provide advanced knowledge in business; health and education; pharmacy studies; science and humanities; as well as communication. In addition, Husson University has a robust adult learning program. For more information about educational opportunities that can lead to personal and professional success, visit Husson.edu.
While Husson University prides itself as a teaching institution, the importance of faculty scholarship and research to
Connecticut Pharmacists Association Fall CE Series Live, 5-credit CE program with Law and Immunization •
October 20, 2016
Farmington Marriott 8am-1:15pm
•
November 16, 2016
Trumbull Marriott 1pm-6:15pm
•
December 9, 2016
Inn at Middletown 8am-1:15pm
Call 860-563-4619 for more information or log onto www.ctpharmacists.org in September for more registration information.
32
Pharmacy Journal of New England • Summer 2016
Massachusetts College of Pharmacy and Health Sciences – Boston Dear Colleagues, On behalf of President Charles F. Monahan and Provost George Humphrey, I bring you greetings from MCPHS University and hope that the summer finds you well. We just completed another successful academic year culminating with our University-wide Commencement celebration at Gillette Stadium on May 7. Although most of the students are now home for the summer, we are all very active on campus and I would like to share some recent highlights with you. Paul DiFrancesco Dean of Pharmacy
International Initiatives MCPHS University School of Pharmacy-Boston was invited by Kyoto Pharmaceutical University (Japan) to attend KPU’s graduating student research presentations. MCPHS was represented by Dr. Stephen Kerr (Pharmaceutical Sciences), Dr. Cathy Taglieri (Pharmacy Practice), and two PG4students, Sofiya Sovalska and Yousef Hanna. KPU offers a six-year BS program in Pharmacy where students must carry out original research and present this research as part of their graduating requirements. MCPHS was part of six international pharmacy schools attending the student presentations, including USCF, Alexandria University (Egypt), Mahidol University (Thailand) and two universities from Taiwan (National Taiwan and National Cheng Kung University.
New Faculty Stefanie Baker, PharmD, BCPS, has recently joined MCPHS University as an Assistant Professor of Pharmacy Practice. Her practice site is in the ICU at Newton-Wellesley Hospital.
She is a graduate of the University of Wisconsin-Madison School of Pharmacy and completed both PGY-1 and PGY-2 (Critical Care) residencies at Boston Medical Center. Prior to coming to MCPHS, she was a Medical Intensive Care Unit Clinical Specialist at UMass Memorial Medical Center in Worcester.
Faculty Awards Please join me in congratulating three faculty in the School of Pharmacy for receiving student-voted Teacher of the Year Awards. For didactic teaching, the winners were: Paul Kiritsy, Associate Professor of Pharmacy Practice and Dr. Mattia Migliore, Associate Professor of Pharmaceutical Sciences. Dr. Lisa Padgett, Assistant Professor of Pharmacy Practice, won the award for her clinical teaching to students on rotation.
Faculty Promotions I am pleased to announce that five of our faculty have just been promoted in rank and would like to recognize them for this major achievement: Dr. Maria Kostka-Rokosz, Assistant Dean of Academic Affairs and Associate Professor has been promoted to full Professor. Dr. Phil Grgurich, Assistant Professor of Pharmacy Practice has been promoted to Associate Professor. Dr. Kara Bonaceto, Assistant Professor of Pharmacy Practice has been promoted to Associate Professor. Dr. Alejandro Pino, Assistant Professor of Pharmaceutical Sciences has been promoted to Associate Professor. Dr. Nicole Carace, Instructor in Pharmacy Practice, has been promoted to Assistant professor.
Student Volunteers in the Community More than forty MCPHS University PharmD students led by alumnus Dr. Allison Burns, Pharmacy resident at Beth Israel Deaconess Medical Center and CEO of End Mass Overdose Inc., participated in the 2016 Mass Housing Conference: The Opioid Epidemic. Students assisted in the training over three 33
From the Colleges
continued
hundred housing and shelter workers in the demonstration and practice assembly of Narcan. At the end of the session they received high praise from the conference staff on their professionalism and knowledge and were invited to participate again in next year’s conference.
Massachusetts College of Pharmacy and Health Sciences – Worcester/ Manchester Dear Colleagues,
Department of Pharmaceutical Sciences.
The School of Pharmacy-Worcester/Manchester (SOP-W/M) is proud to announce that we graduated 277 students at the May 7 MCPHS University Commencement Ceremony held at Gillette Stadium in Foxboro, MA. We are currently finishing our summer semester and our students are preparing to begin their introductory and advanced pharmacy practice rotations starting in August. I am excited to be serving as the Interim Dean for the SOP-W/M and am looking forward to starting our fall semester.
• Cheryl Durand, Associate Professor of Pharmacy Practice received the MCPHS University SOP-W/M Academic of the Year for the Department of Pharmacy Practice.
Sincerely, Anna K. Morin, PharmD Interim Dean and Professor of Pharmacy Practice
Faculty Awards At the MCPHS University SOPW/M annual awards ceremony held on May 2, the following faculty members were recognized for their outstanding teaching, scholarship and service to the University and its students: • Alice Gardner, Professor of Pharmacology received the MCPHS University SOPW/M Academic of the Year for the 34
Alice Gardner
• Mimi Mukherjee, Assistant Professor of Pharmacy Practice received the MCPHS University SOP-W/M Preceptor of the Year. At the MCPHS University Faculty Meeting on May 3, Morgan Comee, Assistant Professor of Pharmacy Practice, Amanda Morrill, Assistant Professor of Pharmacy Practice, and Katherine Carey, Associate Professor of Pharmacy Practice received the Scholarship of Teaching Award for their publication titled “Evaluation of a hybrid ambulatory care elective for first year pharmacy students” (Citation: Curr Pharm Teach and Learn 2016;8(1):104-11). Kevin Kearney, Professor of Pharmaceutical Sciences received the 2016 MCPHS University Trustees’ Award for Teaching for the Worcester and Manchester campuses during the May 2016 MCPHS University Commencement Ceremony. This is the University’s highest teaching award; candidates are nominated by their peers and students and Kevin Kearney are chosen by a panel of students and past award recipients based on their
Pharmacy Journal of New England • Summer 2016
teaching portfolio.
New Faculty The SOP-W/M welcomes Michael Bear, PharmD as an Assistant Professor in the Department of Pharmacy Practice. Michael received his undergraduate degree at Boston University in 2007 and his PharmD at the State University of New York Buffalo in 2014. After earning his PharmD, he completed a PGY1 Residency at Tufts Medical Center in Boston, MA and then a 1-year fellowship in Geriatric Pharmacy with the MCPHS Pharmacy Outreach program. Michael’s clinical site will be at the UMASS University campus in Worcester, MA.
Faculty Publications Binkowski C, Hartung J, Towle J, Cooper M. Profile of ramucirumab in the treatment of metastatic non-small cell lung cancer. Onco Targets Ther. April 2016. (9)1953–1960. Towle, J. Water Pollution (Prescription Drugs). In: Boslaugh SE. The Sage Encyclopedia of Pharmacology and Society. Thousand Oaks, CA: Sage Publications, Inc.;2016:1532-1534. Waly M, Power-Charnitsky VA, Hodgson N, Sharma A, Audyha T, Zhang Y, Deth R. Alternatively Spliced methionine synthase in SH-SY5Y neuroblastoma cells: cobalamin and GSH dependence and inhibitory effect of neurotoxic metals and thimerosal. Oxidative medicine and Cellular Longevity. 2016.
Faculty Podium Presentations Dr. Karyn Sullivan, PharmD, MPH presented her work on “Assessing the Utilization of a New Insomnia Order Set in a Community Hospital” at the David Spodick Clinical Investigator Symposium, Saint Vincent Hospital. Worcester, MA, April 7, 2016.
American Pharmacists Association Annual Clinical Meeting. Washington, DC. March 2016. Al-Hubaishi A, Alsaffar R, Gardner A. The role of exchange protein directly activated by cAMP (Epac) as a novel regulator of airway smooth muscle functions in asthma. 2015 American Society of Health System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition. New Orleans, LA. December 2015. Lowe K, Hor K, Smith C. Synthetic studies toward a triazolotriazine scaffold as part of the Open Source Malaria Project, MCPHS SOP (W/M) Research Day, Worcester, MA, April 13, 2016. Liu J, Smith C. Open Source Malaria Project. MCPHS University SOP (W/M) Research Day. Worcester, MA. April 13, 2016. Liu J, Smith C. Open Source Malaria Project. Northeast Student Chemistry Research Conference, Boston, MA, April 16, 2016. Alsaffar R, Gardner A. The role of Epac as a novel regulator of airway smooth muscle proliferation in asthma. ATS International Conference. San Francisco, CA. May 13-18, 2016. Al Suliman B, Gardner A. CYP1 P450 via an EETs mechanism controls NF-kB signaling in asthmatic airway smooth muscle. ATS International Conference. San Francisco, CA. May 13-18, 2016. Bahauddin A, Gardner A. ET-1 enhances EGFR phosphorylation via Src activation in asthmatic airway smooth muscle. ATS International Conference. San Francisco, CA. May 13-18, 2016.
Faculty Poster Presentations Gibson S, Towle J, Abel C. Pharmacist perceptions of signs and symptoms of drug abuse and knowledge of resources for referal. American Pharmacists Association Annual Clinical Meeting. Washington, DC. March 2016. Dunican KC, Abel CA, Comee M, Donovan JL, Horton ER, Morin AK, Morrill AM. Incoming student pharmacists readiness to participate in interprofessional learning. 35
From the Colleges
continued
Northeastern University Northeastern Receives $9M grant to fast track the discovery of new antibiotics
In September 2014, President Obama issued an executive order for “Combating Antibiotic Resistant Bacteria.” Why the urgency? The Centers for Disease Control and Prevention, the order noted, “estimates that annually at least 2 million illnesses and 23,000 deaths are caused by antibiotic-resistant bacteria in the United States alone.” This month, a team led by Northeastern University Distinguished Professor of Biology Kim Lewis received a five-year, $9 million grant from the National Institutes of Health’s Kim Lewis National Institute of Allergy and Infectious Diseases to develop a novel platform to translate the president’s order into action. The award will enable the team to expand on the pioneering research of Lewis and Distinguished Professor of Biology Slava Epstein. The pair used an innovative method to grow “unculturable” bacteria in the lab, leading to the discovery of a new antibiotic that kills pathogens without encountering any detectable resistance. Called teixobactin, the antibiotic eliminated the superbug MRSA, or methicillin-resistant Staphylococcus aureus, in mice as well as numerous other pathogens. The new platform will facilitate quick identification of new antibiotics such as teixobactin, says Lewis, who is also director of the Antimicrobial Discovery Center. “There are a number of bottlenecks in natural product discovery,” he says. “Our aim is to resolve these bottlenecks and improve our efficiency by a couple of orders of magnitude.” Indeed, as the authors write in a paper they recently submitted, the platform “has strong potential to return us to the golden age of antibiotic discovery.”
36
The Well Runs Dry In that golden age, researchers discovered new antibiotics by screening soil for microorganisms that produced compounds lethal to other pathogens. But that well essentially ran dry by the late 1960s, and the bacteria had acquired mutations that rendered them resistant to the once effective antibiotics. Lewis and Epstein’s breakthrough was in finding a way to tap into the 99 percent of soil-based microorganisms that won’t grow in a lab. They used a small device developed by Epstein’s group called the iChip that isolates and grows individual bacterial cells in their natural soil environment. The breakthrough led to Lewis and Epstein co-founding NovoBiotic Pharmaceuticals, in Cambridge, Massachusetts. Amy Spoering, PhD’05, who now works at NovoBiotic, is a co-investigator on the new NIAID grant. From the uncultured bacteria they identified 25 new antibiotics, among them teixobactin and lassomycin, which acts against Mycobacterium tuberculosis. Still, says Lewis, the process left certain elements up to chance. “We had no idea whether the soil harbored interesting microorganisms or didn’t,” he says. “So then the obvious question became: Why not take a step back and screen the soils themselves before isolating individual bacteria?”
On the Fast Track to Discovery The new platform uses sophisticated genomic technologies and bioinformatics tools to do just that. With co-investigator Karen E. Nelson, president of the J. Craig Ventor Institute, in La Jolla, California, the researchers will extract DNA straight from the soil samples and, using genetic sequencing, determine the diversity of the microorganisms within and identify each one by type. “It’s a one-step process,” says Lewis. “Based on experience we will then know right away whether the soil contains the types of bacteria that have historically been linked to antibiotic production.” The initial soil samples, says Lewis, will come from Northeastern property, including that in Nahant,
Pharmacy Journal of New England • Summer 2016
Massachusetts, home of the university’s Marine Science Center. Currently, once researchers identify a promising bacterium based on its ability to inhibit a pathogen, say, MRSA, they take an extract from it and chemically analyze the extract’s characteristics. “It’s a laborious process, an enormous bottleneck,” says Lewis. “And the vast majority of things found in producing bacteria are junk. Finding a compound that’s useful is like searching for a needle in a haystack.” The new platform fast-tracks the process. The extracts will be analyzed not chemically but biologically, displaying what
genes the target pathogen expresses when treated with an extract containing an antimicrobial compound. “From that pattern of gene expression we can deduce the mode of action of the compound and make a call about its potential usefulness,” says Lewis. Finally, Lewis will test the selected compounds to map their mechanism of action in detail and then validate their effectiveness against a host of pathogens both in cell cultures and a mouse model. “I think that we are going to find many novel antibiotics,” says Lewis. “We are very excited about this opportunity.”
Pharmacists Mutual Insurance Company Named a 2016 Ward Group Top 50 Property-Casualty Insurance Company Advertisement (Algona, IA) Pharmacists Mutual is proud to announce that it has been named to the 2016 Ward’s 50 Benchmark Group of top-performing insurance companies in the United States. Being named to this group recognizes Pharmacists Mutual for achieving results in the areas of safety, consistency, and performance over a five year period (2011-2015). “Over the past five years, we have worked to instill a results oriented culture while preserving our member service focus,” said Ed Yorty, President and CEO of Pharmacists Mutual. “I am gratified to see those efforts recognized. The recognition as a Ward’s 50 company would not have occurred without our great team of employees.” Jon Grether, Chief Operating Officer of Pharmacists Mutual also noted, “There have been a lot of changes in our organization over the past five years, all in an effort to become more efficient and effective for our members. Being ranked in the top 2% of all property and casualty insurance companies in the United States by being named a Ward 50 company is a high honor.” Ward Group, a Cincinnati, Ohio-based consulting and benchmarking firm that specializes in the insurance industry, annually reviews the operations of over 3,000 Property/Casualty insurance companies, selecting the top 50 performers. This group of 50 companies is referred to as the “Ward’s 50.” Currently licensed in 50 states, the District of Columbia, and Puerto Rico, Pharmacists Mutual Insurance Company provides professional liability, business, and personal insurance products for its core markets of pharmacy, dentistry, home medical/home health, grocery and card and gift stores. Pharmacists Mutual Insurance Company strives “To help our customers attain peace of mind through specialized insurance products, risk management solutions, and superior personal service.” Learn more at www.phmic.com or call 800.247.5930.
37
From the Colleges
continued
University of New England College of Pharmacy Alumna Tyla Hagan Named Pharmacist of the Week Pharmacy News Today has selected Tyla Hagan, Pharm.D. ’14, as Maine’s Pharmacist of the Week. In a web feature highlighting her achievement, Hagan states that the most rewarding aspect of her job is creating innovative ways to enrich the lives and health of patients. A news service provider and professional services company, Pharmacy News Today provides comprehensive prescription and pharmacy-related news to pharmacists, pharmacy technicians, students and industry professionals. Read Hagan’s web feature.
Daniel Mickool Selected to Present at University of Oxford Daniel Mickool, R.Ph., M.S., (Ed.D. ’17), director of continuing education, has been selected to speak at the All Together Better Health VIII conference, to be held September 6-9 at the University of Oxford in the U.K. Chosen by peer review from a competitive pool of applicants, Mickool will present “A discussion and review of building a collaborative practice in order to optimize patient outcomes and teach learners interprofessional communication skills.” The All Together Better Health conference is the leading international interprofessional practice and education conference under the direction of the World Coordinating Committee. It is attended by health providers, executives, educators, policymakers and healthcare industry leaders from across the globe. 38
Emily Dornblaser and Leslie Ochs Published in the American Journal of Pharmaceutical Education Emily Dornblaser, Pharm.D., MMEL, and Leslie Ochs, Pharm.D., Ph.D., MSPH, both assistant professors in the College of Pharmacy, have been published in the American Journal of Pharmaceutical Education (AJPE). Dornblaser co-authored a paper titled “Current Practices in Global/International Advanced Pharmacy Practice Experiences: Home/Host Country or Site/Institution Considerations.” As international outreach by pharmacy schools is increasing, Dornblaser and her colleagues set out to establish a set of best practices for exchange programs and practice experiences. Their paper provides current practice guidelines to establish and maintain successful global/ international advanced pharmacy practice experiences (G/I APPEs) with specific recommendations for home/host countries and host sites/institutions. Both Dornblaser and Ochs were co-authors of a paper titled “Current Practices in Global/International Advanced Pharmacy Practice Experiences: Preceptor and Student Considerations.” Their article described key areas of consideration for G/I APPE preceptors, students and learning objectives. Read Dornblaser’s paper. Read Dornblaser and Och’s paper.
UNE Interprofessional Grant Recipients Featured in the American Journal Dental hygiene student Regina Arey (’17) and her interprofessional colleagues were featured in the American Journal for their UNE IPEC Mini-grant project. After observing the dental care provided to one of her
Pharmacy Journal of New England • Summer 2016
relatives in a nursing home, Arey was inspired to develop a student-led project to address oral healthcare issues in the aging population. For their IPEC Mini-grant, Arey and student collaborators Sarah Fogg (Dental Hygiene, ’17), Carolyn Dacey (Dental Hygiene, ’17), Cassidy Banville (Dental Hygiene, ’17), Kelly Dolyak (MSOT, ’17) and Casey Fisher (COP, ’19) conducted training sessions for the staff at the Gorham House comprehensive living center in Gorham, Maine. In the trainings, the students first spoke with staff and residents to assess their questions and concerns regarding oral care. They then created an educational presentation tailored to these questions, addressing the need for daily brushing, flossing and cleaning of partials or dentures. In addition, they discussed oral bone degeneration, as well as the issue of dry mouth caused by medications. Dental models were utilized to demonstrate proper flossing and flossing technique, as well as denture cleaning. Speaking about the project, Arey stated “I truly believe this interprofessional project will not only benefit the students and staff involved but also the community as a whole.” Read the article.
Hershey Bell Speaks at College of Pharmacy Hooding Ceremony Hershey S. Bell, M.D., M.S. (Medical Education), FAAFP spoke at the hooding ceremony for UNE’s College of Pharmacy on May 22. Bell is currently the Vice President for Academic Affairs, Dean of the School of Pharmacy and a professor of Family Medicine and Pharmacy Practice at Lake Erie College of Osteopathic Medicine (LECOM) in Erie, Pennsylvania and Bradenton, Florida. A graduate of the Faculty of Medicine at the University of Toronto, Bell completed family medicine residency education at the University of Toronto and Duke University. Following residency, he served as a Duke University National Faculty Development Fellow.
Above, from L to R: Kelly Dolyak, Regina Arey, Sarah Fogg, Carolyn Dacey, Cassidy Banville, and Casey Fisher.
At the hooding cermoney, graduates of the program received their academic hoods and recite The Oath of a Pharmacist.
Leslie Ochs Selected as an AACP Academic Leadership Fellow Leslie Ochs, Pharm.D., Ph.D., MSPH, assistant professor in the College of Pharmacy, have been chosen as to participate in the American Association of Colleges of Pharmacy (AACP) Academic Leadership Fellows Program in 2016-17. As described by the AACP, this highly selective program is designed to “develop the nation’s most promising individuals at our member institutions to become future leaders in pharmacy and in higher education.” Ochs was one of only 30 faculty members nationwide to be chosen for the program. Over the next year, Ochs will take part in several leadership training activities, culminating with graduation from the program at the AACP annual meeting next summer.
Bangor Daily News Article Highlights UNE Rural Health Immersion in Aroostook County The Bangor Daily News published an article about 15 University of New England students who recently traveled to Aroostook County to learn more about the importance of inteprofessional education and rural health care. The medical, dental and pharmacy students traveled with Jennifer Gunderman, B.S., M.P.H. assistant lecturer of Public Health and Dora Anne Mills, M.D., M.P.H., F.A.A.P., University of New England vice president for Clinical Affairs and director for the Center for Excellence in Health Innovation.
39
From the Colleges
continued
During the trip, students visited hospitals and clinics, met with community leaders and took part in clinical training exercises where they worked as a team, including a simulated rapid intubation exercise at The Aroostook Medical Center in Presque Isle. The article described UNE’s interdisciplinary approach to training future health care providers, many of whom will go on to practice primary care in rural settings. Mills says interprofessional education is critical in reducing medical errors. “The most common medical error deaths are from infections, many of them from urinary tract infections,” she said. “Those infections can lead to life-threatening conditions like the blood infection sepsis, and they can often be traced back to failures of communication or coordination.” Read the article.
The College of Pharmacy Class of 2016 Gives Local Artists’s Mural as Class Gift UNE College of Pharmacy Class of 2016 has given a mural by local artist Justin Giacobbi as the class gift. Painted with acrylic over a series of 14 panels, the mural has been installed at the College of Pharmacy’s main entrance. Bold and energetic, the artwork features a mix of Maine themes; traditional pharmaceutical symbols, including the Bowl of Hygeia and chemical compositions; and UNE imagery. In creating the work, Giacobbi said that he strived to capture the perspective of the 2016 graduates, working with faculty and students to develop the concept. Giacobbi, who is a member of the Coast Guard, has been creating art since the age of four and views it as a way of maintaining balance in his life. “I express emotion through the canvas,” he stated. “Art is my fire inside; my passion.”
Remembering Dr. Douglas H. Kay It is with sadness that we inform you of the recent passing of Douglas H. Kay, whose involvement in UNE’s College of Pharmacy spanned many years and whose deep commitment to the College was unparalleled. From the time he arrived at UNE in 2007 as the special assistant to the dean of the College of Pharmacy to his position as executive associate dean in 2008 and subsequent appointment to dean in 2009, Doug was a gentleman of the old school and an exemplary administrator who always 40
had students at the heart of his work. He and his wife Dottie were beloved by all who knew them. It has been said that everyone in pharmacy is at most two
Douglas H. Kay
or three colleagues removed from Dr. Kay; and, indeed, the influence he had on generations of pharmacists is beyond measure. Licensed as a pharmacist in 1953, Doug was appointed dean and professor of Pharmaceutical Chemistry at the School of Pharmacy, Duquesne University in Pittsburgh, PA in 1981. During his tenure as dean, the school grew to become the sixth largest pharmacy school nationally for enrollment. The quality of the student body remained strong with about 40 percent of the pharmacy students being named to the Dean’s List each semester. From 1988 to 1998, the graduate school enrollment tripled to about 50 students equally divided between M.S. and Ph.D. programs in pharmaceutics, medicinal chemistry and pharmacology/toxology. With Doug at the helm, Faculty Collaboration/Exchange Agreements were established between the School of Pharmacy and the Schools of Pharmaceutical Sciences at Kobe Gakuin University in Kobe, Japan, in 1991 and Beijing Medical University in Beijing, China, in 1997. Doug was active at the national level in several pharmacy organizations. He served the Rho Chi Honor Society as National Secretary (1977-81), national vice-president (198183), and as national president (1984-86). He was editor of the Report of Rho Chi from 1977-83. He received the organization’s Distinguished Service Award in 1988 and 1998. He served the Phi Delta Chi Fraternity as grand vice president of Collegiate Affairs (1967-69), grand president (1969-71) and grand past president (1971-73). He served as a member of the fraternity’s Board of Counselors from 1986-1998. Doug was also actively involved in AACP activities as both a member of the Council of Faculties and Council of Deans. He
Pharmacy Journal of New England • Summer 2016
served as chair of the Council of Faculties Nominating Committee (197576) and Resolutions Committee (1977-78). He was a member of the Academic Affairs Committee in 1979-80. On the Council of Deans he served as a member (1979-90) and chair (1980-81) of the Resolutions Committee; as Secretary (1983-1987); as chairelect (1987), and as chair (1987-88) and immediate past chair (1988-1990). From 1987-1990 he was a member of the Board of Directors. Ten years before UNE’s College of Pharmacy admitted its first class, Doug led a feasibility analysis to justify the need for a pharmacy school. Many at UNE were fortunate to experience his calm and confident leadership first-hand. Most alumni in our inaugural pharmacy class think of Doug as the founding dean because he was the chief academic officer of the college when we opened our doors in the fall of 2009.
George Allen and Pharmacy Student Kayla Harris Present at ASM Microbe 2016 Conference George Allen, Pharm.D., associate professor and chair of the Department of Pharmacy Practice, and Kayla Harris (COP ’18) presented at the American Society for Microbiology (ASM) Microbe 2016 conference, held June 16-20 in Boston. Their poster, titled “In vitro evaluation of resistance selection in Shigella flexneri by azithromycin, ceftriaxone, ciprofloxacin, levofloxacin, and moxifloxacin,” illustrated their research of various antimicrobials against Shigella flexneri. The Centers for Disease Control and Prevention has identified Shigella flexneri as bacteria that poses a serious threat as an antimicrobial resistant pathogen. The first of its kind, the ASM Microbe 2016 conference explored the scope of microbiology from basic science all the way to clinical application. This meeting, comprised of the largest gathering of microbiologists in the world, was devoted to the topics of antimicrobial resistance, new antimicrobial development, antimicrobial stewardship, and the diagnosis, prevention, and treatment of infectious diseases.
During the College of Pharmacy’s 2010 ACPE site accreditation visit, Doug was the most senior dean of any U.S. college of pharmacy. He is remembered as a resilient and determined man who came to work well after he had retired on the worst of Maine winter days in a wheelchair, to make sure that the college remained on track toward accreditation. The ACPE accreditation team even respectfully referred to him as a “Dean of Deans.” The Doctor of Pharmacy Class of 2013 honored Doug by placing a sundial in the center of the College of Pharmacy medicinal herb garden in recognition of his outstanding commitment and service to the UNE College of Pharmacy. Also in 2013, he was recognized by the Maine Pharmacy Association with the Bowl of Hygeia for his outstanding record of civic and professional leadership. The University held a service for Doug on June 24.
Kayla Harris and George Allen
Allen, Harris and Kelly Sawyer (COP ’18) also attended the Society of Infectious Diseases Pharmacists (SIDP) Annual Meeting on June 16 in Boston. This meeting included presentations concerning the management of antimicrobialresistant bacteria, responsible use of antimicrobials in animals and agriculture, and antimicrobial stewardship. 41
From the Colleges
continued
University of St. Joseph School of Pharmacy
Message from the Dean Dear Colleagues: We, with your support, continue in our commitment in educating future leaders into our wonderful profession of Pharmacy. With your help as preceptors, we just graduated our third cohort of promising and enthusiastic professionals who bring innovative ideas in helping solve some of the challenges we face in healthcare today. I am pleased to announce that the full accreditation status of University of Saint Joseph School of Pharmacy has been continued by the Accreditation Council Pharmacy Education Board of Directors for its customary accreditation term. Thank you to you all – your support made these achievements possible. Always, Best, Joseph R. Ofosu Founding Dean and Professor, USJ School of Pharmacy
New Appointment Dr. Steven Lemieux joined the School of Pharmacy as an Assistant Professor in the Department of Pharmacy Practice and Administration. Dr. Lemieux is a graduate of the University of Connecticut. He completed a PGY-1 pharmacy residency at John Dempsey Hospital in Farmington, CT and a PGY-2 critical care residency at Yale-New Haven Hospital in New Haven, CT. Dr. Lemieux will establish an acute care practice at Yale-New Haven Hospital and will contribute to courses in drug information, renal pharmacotherapy, and therapeutics of gastrointestinal disorders.
members of the class in recognition of their service, leadership and academic achievement, and the officers of the Class of 2016 presented a gift to the School of Pharmacy. The Marguerite M. Miceli Memorial Award has been established in memory of Ms. Marguerite M. Miceli who would have been part of the graduating Class of 2015. This award is given annually to two graduating students who have made significant improvements in academic performance in the pharmacy program and have demonstrated sound character and true passion for a career in pharmacy. The two recipients for 2016 were Mitchell Namias and Sonal Patel. It was a special moment for the entire student body and all the guests who were in attendance.
News The Hooding, Oath and Awards Ceremony for the Doctor of Pharmacy Class of the University of Saint Joseph was held on Friday, May 6, 2016 at the Hoffman Auditorium of the Bruyette Athenaeum on the main campus of the University. The eightyone graduates were assisted in donning their doctoral hoods by members of the School of Pharmacy faculty. They were then led in reciting the Pharmacist’s Oath by Dean Joseph R. Ofosu. Eighteen awards were presented to 42
Dayne Laskey, Pharm.D., DABAT, Assistant Professor of Pharmacy Practice & Administration,is pictured (above) at the far right.
USJ alumni had a guided tour of the School of Pharmacy Medicine Garden with Dr. Dayne Laskey, Assistant Professor at the School of Pharmacy, and a guided tour of the Rose Garden with Kathy Kraczkowsy, USJ Ambassador during the annual “Walk through Elizabeth Park” on Thursday, June 16.
Pharmacy Journal of New England • Summer 2016
Posters and Presentations Emma Gimose and Edafiogho IO. “Synthesis of imidooxy compounds as potential anticancer agents.” Poster Presentation, Symposium Day, University of Saint Joseph, April 14, 2016. Iregi Francis and Edafiogho IO. “Synthesis of dibromophenyl enaminones as potential anticonvulsant compounds.” Poster Presentation, Symposium Day, USJ, April 14, 2016. Above, pictured from L to R: Akil Shaikh, Stephanie Forgette, Angela Fortune, and Yolande Lum
School of Pharmacy students promoted smoking and tobacco cessation in McGovern Hall as the University of Saint Joseph becomes a smoke-free and tobacco-free campus on June 1. On Friday May 13th SSHP members of the Heart Health Awareness Committee had a successful blood pressure drive and CPR awareness event at the XL Center.
Catherine Bobea and Slauson SR. “Studies Toward a Diels-Alder Reaction for Epibatidine Analogs.” Poster Presentation, Symposium Day, University of Saint Joseph, April 14, 2016. Andrea Aquilato and Szollosi DE. “Do the JODI Series Compounds Promote the M2 Macrophage (Anti-Inflammatory) Status?” Poster Presentation, Symposium Day, University of Saint Joseph, April 14, 2016. Natasha Weiner and Szollosi DE. “The Mechanism of Action of JODI series Compounds on LPS-Stimulated Macrophages.” Poster Presentation, Symposium Day, USJ, April 14, 2016. Natalia Rosa and Mandela P. “SSRI’s induced behavioral alterations in Drosophila.” Poster Presentation, Symposium Day, University of Saint Joseph, April 14, 2016. Amanda Post and Sweezy MA “The Biochemical Activities of the Rhp51 Protein of Schizosaccharomyces pombe and its Role in Homologous Recombination Repair.” Oral Presentation, Symposium Day, USJ, April 14, 2016.
Above, pictured from L to R: Catherine Stirbis, John Pernyeszi, Karina Soares, Van Vu, Andrea Aquilato and Natasha Weiner
The Organ Donor Awareness Project at the 2016 NKF Kidney Walk held at Wickham Park on May 1. To the right, pictured from L to R: Chelsea McLoughlin, Anika Rehman, Nesti Risto, Jaclyn Kowalski and Meredith Gilbert
43
From the Colleges
continued
Lydia Tran, Ghoneim OM, and A.A. Khalil, SAR of “Phenoxyacetic Acid Analogs as Synergistic Dual Activity Serotonergic Ligands for Potential Use in ASD.” Poster presentation at the 2016 International Meeting for Autism Research, Baltimore Maryland, May 11-14, 2016. Leschak, A. “Medication Reconciliation: Improving transitions of care in a long term care setting.” Webinar for Qualidigm. INTERACT: Quality Improvement Tool and Medication Reconciliation Tool. Wethersfield, CT. May 25, 2016 Laskey D. “Drug Abuse in the 21st Century,” Continuing Education Series on Enhancing Medication Safety for Registered Pharmacists.” Western New England University, Springfield MA. UAN 0576-0000-16-016-L01-P. [June 2016] Szollosi DE, Ghoneim OM, Manzoor M, Dhuguru J, Edafiogho IO. ”Characterization of piperazino-enaminone compounds as novel anti-inflammatory agents.” 16th Annual Meeting of the Federation of Clinical Immunology Societies 2016, June 23, 2016.
Publications Ghoneim OM, Alper RH, Szollosi DE. Sweezy MA, Vadlapatla R, Edafiogho IO. “Implementation of an Elective Course to introduce Pharmaceutical Sciences Research” Currents in Pharmacy Teaching and Learning, Volume 8, issue 4, July-August 2016 Summa, MA. “SGLT-2 Inhibitors.” Core Content Rev Fam Med 2016;47(3):31-33. Linder K, Krawczynski M, Laskey D. Sodium Zirconium Cyclosilicate: A Novel Agent for the Treatment of Hyperkalemia. Pharmacotherapy. In press Haines SL, Dy-Boarman EA, Clifford KM, Summa MA, Willson, MN, Boyle JA, Peters, MA. Methods Used by US Colleges/ Schools of Pharmacy to Prepare Student Pharmacists for Careers in Academia. Am J Pharm Ed. In press.
See you at the 12th annual
New England Pharmacists Convention September 22 & 23, 2016 Foxwoods Resort Casino Ledyard, CT
44
45